




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 1/20, 15/74, A61K 48/00		A2	(11) International Publication Number: WO 99/45098
			(43) International Publication Date: 10 September 1999 (10.09.99)
(21) International Application Number: PCT/IB99/00587		(81) Designated States: AU, CA, CN, JP, KR, NZ, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 3 March 1999 (03.03.99)			
(30) Priority Data: 09/036,582 6 March 1998 (06.03.98) US		Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(71)(72) Applicants and Inventors: VAN DER BRUGGEN, Pierre, B. [BE/BE]; 12/2, chemin du Relai, B-1325 Corroy-Le-Grand (BE). CORNELIS, Guy, R. [BE/BE]; 2B, avenue des Anciens Combattants, B-1950 Kraainem (BE). BOLAND, Anne, M. [BE/BE]; 159, rue Theodore Decuyper, Boite postale 043, B-1200 Bruxelles (BE). BOON-FALLEUR, Thierry, R. [BE/BE]; 12, rue du Buisson, B-1050 Bruxelles (BE).			
(74) Agent: KOLB, Helga; Hoffmann, Eitle, Arabellastrasse 4, D-81925 München (DE).			

(54) Title: DELIVERY OF PROTEINS INTO EUKARYOTIC CELLS WITH RECOMBINANT YERSINIA

**Anti-MAGE-1.A1 CTL recognize HLA-A1 cells incubated with
Yersinia which produces a YopE130.MAGE-1 fusion protein**



(57) Abstract

The present invention relates to recombinant *Yersinia* and the use thereof for delivery of proteins into eukaryotic cells, including related compositions and methods of treatment and related assays.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

DELIVERY OF PROTEINS INTO EUKARYOTIC
CELLS WITH RECOMBINANT *YERSINIA*

5 The present invention relates to recombinant
 Yersinia and the use thereof for delivery of proteins
 into eukaryotic cells.

 Bacteria of the genus *Yersinia* cause
 diseases in humans and rodents ranging from enteritis
 and lymphadenitis to plague. The genus *Yersinia*
10 encompasses three species: *Yersinia enterocolitica*,
 which is the most prevalent *Yersinia* species in humans
 and causes a broad range of gastro-intestinal
 syndromes; *Yersinia pseudotuberculosis*, which causes
 adenitis and septicaemia; and *Yersinia pestis*, which
15 is the causative agent of plague.

 In spite of the differences in the infection
 routes, these three species of *Yersinia* share a common
 capacity to resist the non-specific immune response of
 the human or rodent host and to proliferate in the
20 host lymphatic tissues. Anatomico-pathological
 examinations revealed that *Yersinia* are not detected
 inside the inflammatory or parenchymal cells of the
 infected animals (Simonet et al. (1990) *Infect. Immun.*
 58: 841-845). Consistent with these in vivo
25 observations, *Yersinia* are resistant to phagocytosis
 in vitro by macrophages and polymorphonuclear
 leukocytes. See review by Cornelis et al. (1997) *Mol.*
 Microbiol. 23(5): 861-867. *Yersinia enterocolitica*
 also has the capacity to enter certain cultured
30 epithelial cells, a process generally referred to as

invasion (Miller et al. (1988) *Infect. Immun.* 56: 1242-1248).

Genetic studies revealed that the virulence of *Yersinia* is determined by a 70 kb plasmid (pYV), which encodes and governs the production of a set of proteins called Yops (for *Yersinia* outer proteins). These Yops form an integrated anti-host system that allows the extracellular adhesion of *Yersinia* to the surface of host cells and the subsequent injection of a set of toxic effector proteins into the host cell's cytosol. Recent studies further revealed that such an anti-host system, also called "*Yersinia* virulon", is composed of the following four elements: (i) a contact or type III secretion system called Ysc, which is devoted to the secretion of Yop proteins out of the bacterial cells; (ii) a set of "translocators" for translocating the effector proteins into the eukaryotic host cells, which consist of YopB, YopD and possible other proteins such as LcrV; (iii) a control element and recognition system (YopN and LcrG); and (iv) a set of "effector proteins" including YopE, YopH, YopO/YpkA, YopM and YopP/YopJ, which are injected (or translocated) into the eukaryotic host cells and disrupt the functions of such host cells. Transcription of these genes is controlled both by temperature and by contact with a eukaryotic cell. See review by Cornelis et al. (1997).

The effector proteins disrupt the function of host cells in a number of ways. The 23 kd YopE is a cytotoxin that disrupts the actin-microfilament structure of cultured Hela cells (Rosqvist et al.

(1990) *Mol. Microbiol.* 4: 657-667; Rosqvist et al.
(1991) *Infect. Immun.* 59: 4562-4569). The 51 kd YopH
is a protein tyrosine phosphatase (PTPase) related to
eukaryotic PTPases, which acts on tyrosine-
5 phosphorylated proteins of infected macrophages
(Hartland et al. (1994) *Infect. Immun.* 62: 4445-4453).
Presumably as a result of this action, YopH inhibits
bacterial uptake and oxidative burst by cultured
macrophages (Rosqvist et al. (1988) *Infect. Immun.*
10 56: 2139-2143; Bliska et al. (1995) *Infect. Immun.* 63:
681-685). YopO (or YpkA) is an 81 kd serine/threonine
kinase, which is targeted to the inner surface of the
plasma membrane of the eukaryotic cell and might
function to interfere with the signal transduction
15 pathway of the eukaryotic cell (Hakansson et al.
(1996) *Mol. Microbiol.* 20: 593-603). YopM is an
acidic 41 kd protein having 12 leucine-rich repeats,
which suggests that YopM might bind thrombin and
interfere with platelet-mediated events of the
20 inflammatory response (Leung et al. (1989) *J.*
Bacterial. 171: 4623-4632). YopP is involved in the
induction of apoptosis in macrophages (Mills et al.
(1997) *Proc. Acad. Natl. Sci. USA* 94: 12638-12643).
The molecular structures of these effector
25 proteins have been investigated to determine the
elements in each effector protein that are required
for their secretion and translocation. For this
purpose, hybrid proteins have been engineered by
fusing truncated Yop effector proteins of different
30 length with certain reporter enzymes such as the
calmodulin-activated adenylate cyclase domain (or Cya)

of the *Bordetella pertussis* cyclolysin. Successful secretion and/or translocation events could be detected by assays based on the enzymatic activity of the reporter protein. Sory et al. disclose, by
5 applying this approach, that YopE and YopH of *Y. enterocolitica* are modular proteins composed of three domains, i.e., an N-terminal domain required for secretion, a translocation domain required for translocation into cells, and a C-terminal catalytic
10 domain responsible for the toxic effector activity. Sory et al. (1995) *Proc. Natl. Acad. Sci. USA* 92: 11998-12002. The same domain organization has been demonstrated for YopM of *Y. enterocolitica* (Boland et al. (1996) *EMBO J.* 15: 5191-5201).

15 The present invention provides recombinant *Yersinia* for safe delivery of proteins into eukaryotic cells. Such *Yersinia* are deficient in the production of functional effector proteins, but are endowed with a functional secretion and translocation system. The
20 present invention further provides expression vectors for use in combination with such mutant *Yersinia* for safe and efficient delivery of desired proteins into eukaryotic cells. This approach is useful not only for studying the function of a given protein, but also
25 for designing therapeutic approaches. For example, a protein of a pathogenic origin, e.g., a tumor associated protein, a parasite antigen, or a viral antigen, can be delivered using the recombinant *Yersinia* of the present invention into antigen
30 presenting cells for inducing an immune response specific for such a protein.

Most progressively growing neoplastic cells express potentially immunogenic tumor-associated antigens (TAAs), also called tumor rejection antigens (TRAs). TRAs, like other antigenic epitopes, are presented at the surface of tumor cells by MHC molecules and have been shown to induce a CTL response *in vivo* and *in vitro*. See, for example, van der Bruggen et al. (1991) *Science* 254: 1643-1647. However, such TRA-expressing tumor cells do not provoke reliable anti-tumor immune responses *in vivo* that are capable of controlling the growth of malignant cells. Boon et al. (1992) *Cancer Surveys* 13: 23-37; T. Boon (1993) *Int. J. Cancer* 54: 177-180; T. Boon (1992) *Advances Cancer Res.* 58: 177-209.

A number of genes have been identified that encode tumor rejection antigen precursors (or TRAPs), which are processed into TRAs in tumor cells. Such TRAP-encoding genes include members of the MAGE family, the BAGE family, the DAGE/Prame family, the GAGE family, the RAGE family, the SMAGE family, NAG, Tyrosinase, Melan-A/MART-1, gp100, MUC-1, TAG-72, CA125, mutated proto-oncogenes such as p21ras, mutated tumor suppressor genes such as p53, tumor associated viral antigens such as HPV16 E7. See, e.g., review by Van den Eynde and van der Bruggen (1997) in *Curr. Opin. Immunol.* 9:684-693, Sahin et al. (1997) in *Curr. Opin. Immunol.* 9:709-716, and Shawler et al. (1997) *Advances in Pharmacology* 40: 309-337 Academic Press, Inc.: San Diego, California. The identification of these genes has allowed recombinant production of TRAs

or TRAPs which may be subsequently used as vaccines to treat various cancerous conditions.

5 The present invention contemplates the use of recombinant *Yersinia* for delivery of desired proteins into eukaryotic cells. Particularly, the recombinant *Yersinia* of the present invention are useful for delivery of proteins or derivatives thereof to antigen presenting cells. In accordance with the present invention, antigen presenting cells upon receiving the delivery, present antigenic epitopes which can be recognized by T cells. Thus, the recombinant *Yersinia* of the present invention can be employed in a number of immune diagnostic or therapeutic approaches.

15 The present invention is further elaborated upon the following disclosure.

The present invention relates to recombinant *Yersinia* and the use thereof for delivery of proteins into eukaryotic cells.

20 One embodiment of the present invention provides mutant *Yersinia* strains deficient in producing functional effector proteins. A preferred mutant *Yersinia* strain of the present invention is a quintuple-mutant strain designated as *yopEHMOP*.

25 Another embodiment of the present invention provides expression vectors for delivery of heterologous proteins to eukaryotic cells. In accordance with the present invention, such an expression vector is characterized by (in the 5' to 3' direction) a promoter, a first nucleic acid sequence encoding a delivery signal, a second nucleic acid

30

sequence fused thereto coding for a heterologous protein to be delivered.

According to this embodiment of the present invention, the promoter is preferably one from a
5 *Yersinia* virulon gene; more preferably, an effector-encoding gene; even more preferably, a *YopE* gene. The delivery signal is a polypeptide sequence from an *Yersinia* effector, including *YopE*, *YopH*, *YopO/YpkA*, *YopM*, and *YopP/YopJ*. Such delivery signal can be
10 recognized by the secretion and translocation system of *Yersinia*. The heterologous protein of the present invention includes naturally occurring proteins or parts thereof such as tumor-associated proteins or known antigens of pathogens. The heterologous
15 protein of the present invention also includes artificially designed proteins such as in-frame fusion of proteins or parts of proteins.

Yet another embodiment of the present invention provides recombinant *Yersinia*, i.e.,
20 *Yersinia* of the above-described mutant strains further transformed with the expression vector of the present invention. Such recombinant *Yersinia* is preferred for delivery of heterologous proteins into eukaryotic cells. A preferred eukaryotic cell is an antigen
25 presenting cell capable of presenting immunogenic epitopes derived from the heterologous proteins being delivered.

In a further aspect of the present invention, such recombinant *Yersinia* are contemplated
30 in immunogenic compositions and methods for inducing an immune response, either a cellular immune response

or a humoral immune response, or a combination of both.

Further to this aspect of the invention, the recombinant *Yersinia* of the present invention can be employed in an *in vitro* regime for assessing the efficacy of a vaccination regimen. The recombinant *Yersinia* of the present invention can also be employed in an *ex vivo* regime to generate specific CTLs and to use such CTLs for treating various pathological conditions such as tumors or infections by pathogens. The recombinant *Yersinia* of the present invention can also be employed in an *in vivo* regime, i.e., as a recombinant vaccine, to treat subjects suffering pathological conditions such as tumors or infections by pathogens.

Figure 1 illustrates the plasmid map of the expression vector pMS111-MAGE-1 (YopE₁₃₀-MAGE1).

Figure 2 (A) depicts the procedure for stimulating CTL 82/30 with EBV-transformed human B cells (HLA-A1) mixed with recombinant *Yersinia*; (B) depicts the quantitation of IFN- γ released by activated CTLs.

Figure 3 depicts the sequence of the *Yersinia enterocolitica* YopM gene.

Figure 4 depicts the sequence of the *Yersinia enterocolitica* YopE gene.

Figure 5 depicts the sequence of the *Yersinia enterocolitica* YopH gene.

Figure 6 depicts the sequence of the *Yersinia enterocolitica* YopP gene.

Figure 7 depicts the sequence of the *Yersinia enterocolitica* YopP gene.

The present invention relates to recombinant *Yersinia* and the use thereof for delivery of proteins
5 into eukaryotic cells.

In particular, the present invention provides mutant *Yersinia* strains that are deficient in producing functional effector proteins. The present invention further provides an expression
10 vector, which, when transformed into a *Yersinia* of the above-described mutant strains, permits delivery of a desired protein, e.g., a MAGE-1 protein, into a eukaryotic cell, for example, a EBV-transformed human B cell. The present invention provides that, upon
15 receiving the delivered protein, the antigen presenting cell processes the delivered protein and presents antigenic epitopes in the context of an MHC molecule leading to an immune response specific for the protein being delivered. For example, human B
20 cells after taking up the MAGE-1 protein from a recombinant *Yersinia* of the present invention are recognized by a CTL clone specific for a MAGE-1 epitope. Thus the present invention provides an effective recombinant *Yersinia* system with diminished
25 toxicity for delivery of desired proteins into eukaryotic cells.

The term "*Yersinia*" as used herein means all species of *Yersinia*, including *Yersinia enterocolitica*, *Yersinia pseudotuberculosis* and
30 *Yersinia pestis*.

For the purpose of the present invention, the term "recombinant *Yersinia*" used herein refers to *Yersinia* genetically transformed with the expression vectors of the present invention.

5 The term "delivery" used herein refers to the transportation of a protein from a *Yersinia* to a eukaryotic cell, including the steps of expressing the protein in the *Yersinia*, secreting the expressed protein(s) from such *Yersinia* and translocating the
10 secreted protein(s) by such *Yersinia* into the cytosol of the eukaryotic cell. Accordingly, a "delivery signal" refers to a polypeptide sequence which can be recognized by the secretion and translocation system of *Yersinia* and directs the delivery of a protein from
15 *Yersinia* to eukaryotic cells.

 As used herein, the "secretion" of a protein refers to the transportation of such protein outward across the cell membrane of a *Yersinia*. The
20 "translocation" of a protein refers to the transportation of such protein across the plasma membrane of a eukaryotic cell into the cytosol of such eukaryotic cell.

 "Eukaryotic cells" as used herein, the surface of which *Yersinia* adhere to, are also referred
25 to as "target cells" or "target eukaryotic cells".

 One embodiment of the present invention provides mutant *Yersinia* strains which are deficient in producing functional effector proteins.

 The effector proteins of *Yersinia*, i.e., the
30 *Yersinia* virulon proteins which are normally translocated into the cytosol of the target eukaryotic

cells, are toxic to the target cell. Thus, a "functional effector protein" refers to an effector protein having a defined catalytic activity and which is capable of eliciting specific toxicity toward the target cells.

Accordingly, the mutant *Yersinia* of the present invention are used for delivery of proteins to eukaryotic cells, with diminished toxicity, i.e., toxicity which does not completely disable or kill the target cell. For the purpose of delivering proteins, the secretion and translocation system of the instant mutant *Yersinia* need to be intact.

Five effector genes have been cloned from *Y. enterocolitica* which are *YopE*, *YopH*, *YopO*, *YopM*, and *YopP* (Figures 3-7). The equivalent effector genes have been cloned from *Y. pseudotuberculosis* and are named as *YopE*, *YopH*, *YpkA*, *YopM*, and *YopJ*, respectively. Some effector genes have also been cloned from *Y. pestis*. The nucleic acid sequences of these *Yop* genes are available to those skilled in the art, e.g., in the Genbank Database

For the purpose of the present invention, the effector-encoding genes are denoted by italicized letters to be distinguished from the effector proteins. Mutant effector genes are denoted by letters of lower case. For example, *YopE* refers to the effector protein encoded by the *YopE* gene. *YopE* represents the wild type gene, while *yopE* represents a gene having a mutation.

According to the present invention, a mutant *Yersinia* strain can be generated by introducing at

least one mutation into at least one effector-encoding gene. Preferably, such effector-encoding genes include *YopE*, *YopH*, *YopO/YpkA*, *YopM*, and *YopP/YopJ*. The skilled artisan may employ any number of standard techniques to generate mutations in these *Yop* genes. Sambrook et al. describe in general such techniques. See Sambrook et al. (1989) *Molecular Cloning: A Laboratory Manual, Second Edition* Cold Spring Harbor Laboratory Press: Cold Spring Harbor, New York.

The term "mutation" is used herein as a general term and includes changes of both single base pair and multiple base pairs. Such mutations may include substitutions, frame-shift mutations, deletions and truncations.

In accordance with the present invention, the mutation can be generated in the promoter region of an effector-encoding gene so that the expression of such effector gene is abolished.

The mutation can also be generated in the coding region of an effector-encoding gene such that the catalytic activity of the encoded effector protein is abolished. The "catalytic activity" of an effector protein refers to the anti-target cell function of an effector protein, i.e., toxicity. Such activity is governed by the catalytic motifs in the catalytic domain of an effector protein. The approaches for identifying the catalytic domain and/or the catalytic motifs of an effector protein are well within the ken of those skilled in the art. See, for example, Sory et al. (1995), Boland et al. (1996) and Cornelis et al. (1997).

Accordingly, one preferred mutation of the present invention is a deletion of the entire catalytic domain. Another preferred mutation is a frameshift mutation in an effector-encoding gene such
5 that the catalytic domain is not present in the protein product expressed from such "frameshifted" gene. A most preferred mutation is a mutation with the deletion of the entire coding region.

Other mutations are also contemplated by the
10 present invention, such as small deletions or base pair substitutions, which are generated in the catalytic motifs of an effector protein leading to destruction of the catalytic activity of a given effector protein.

15 The mutations that are generated in the *Yop* genes may be introduced into *Yersinia* by a number of methods. One such method involves cloning a mutated *Yop* gene (i.e., a *yop* gene), into a "suicide" vector which is capable of introducing the mutated *yop*
20 sequence into *Yersinia* via allelic exchange. Such "suicide" vectors are described by Kaniga et al. (1991) *Gene* 109: 137-141 and by Sarker et al. (1997) *Mol. Microbiol* 23: 409-411. In this manner, mutations generated in multiple *Yop* genes may
25 be introduced successively into *Yersinia*, giving rise to polymutant recombinant *Yersinia*. The order in which these mutated *yop* sequences are introduced is not important.

30 A preferred mutant *Yersinia* strain of the present invention is a quintuple-mutant *Yersinia* strain in which all the effector-encoding genes are

mutated such that the resulting *Yersinia* no longer produce any functional effector proteins. Such quintuple-mutant *Yersinia* strain is designated as *yopEHOMP* for *Y. enterocolitica* or *yopEHAM* for *Y. pseudotuberculosis*. One example of such *yopEHOMP* strain is *Y. enterocolitica* MRS40 (pABL403).

Under some circumstances, it may be desired to mutate only some but not all of the effector *Yop* genes. For example, when a delivery is intended to target a macrophage, *YopH* is preferably not mutated since *YopH* is understood to inhibit the phagocytosis by macrophages. Rosqvist et al. (1988) and Rosqvist et al. (1989). Accordingly, the present invention further contemplates polymutant *Yersinia* other than quintuple-mutant *Yersinia*, e.g., double-mutant, triple-mutant, and quadruple-mutant *Yersinia*.

Alternatively, the quintuple-mutant strain *yopEHOMP* may still be used for delivery to macrophages, in which case a wild type *YopH* gene can be introduced into the quintuple-mutant *Y. yopEHOMP* strain by various known transformation procedures which are further described hereinafter. In this manner, a polymutant *Yersinia* strain can be generated in which a desired set of *Yop* genes are mutated such that only the protein of interest is delivered into the target cells.

A further aspect of the present invention is directed to an expression vector for use in combination with the instant mutant *Yersinia* strains to deliver a desired protein into eukaryotic cells. In accordance with the present invention, such a

vector is characterized by (in the 5' to 3' direction)
a promoter, a first nucleic acid sequence encoding a
delivery signal, a second nucleic acid sequence fused
thereto coding for a heterologous protein to be
5 delivered.

In accordance with present invention, the
promoter of the expression vector is preferably from a
Yersinia virulon gene. A "*Yersinia* virulon gene"
refers to genes on the *Yersinia* pYV plasmid, the
10 expression of which is controlled both by temperature
and by contact with a target cell. See review by
Cornelis et al. (1997). Such genes include genes
coding for elements of the secretion machinery (the
Ysc genes), genes coding for translocators (YopB,
15 YopD, and LcrV), genes coding for the control elements
(YopN and LcrG), and genes coding for effectors (YopE,
YopH, YopO/YpkA, YopM and YopP/YopJ).

In a preferred embodiment of the present
invention, the promoter is from an effector-encoding
20 gene selected from any one of YopE, YopH, YopO/YpkA,
YopM and YopP/YopJ. More preferably, the promoter is
from YopE.

Further in accordance with the present
invention, a first DNA sequence coding for a delivery
25 signal is operably linked to the promoter.

"A delivery signal", as described
hereinabove, refers to a polypeptide which can be
recognized by the secretion and translocation system
of *Yersinia* and therefore directs the secretion and
30 translocation of a protein into a eukaryotic cell.

According to the present invention, such a polypeptide is from an effector protein. The effector proteins include YopE, YopH, YopO/YpkA, YopM, and YopP/YopJ. Preferably, the effector protein is YopE.
5 More preferably, the effector protein is YopE of *Yersinia enterocolitica*.

One skilled in the art is familiar with the methods for identifying the polypeptide sequences of an effector protein that are capable of delivering a
10 protein. For example, one such method is described by Sory et al. (1994). Briefly, polypeptide sequences from various portions of the Yop proteins can be fused in-frame to a reporter enzyme such as the calmodulin-activated adenylate cyclase domain (or Cya) of the
15 *Bordetella pertussis* cyclolysin. Delivery of a Yop-Cya hybrid protein into the cytosol of eukaryotic cells is indicated by the appearance of cyclase activity in the infected eukaryotic cells that leads to the accumulation of cAMP. Examples of such
20 delivery signal polypeptides include from *Y. enterocolitica*: YopE₁₃₀ (the N-terminal 130 amino acids of YopE), YopE₅₀, YopM₁₀₀ and YopH₇₁.

By employing such an approach, one skilled in the art can determine, if desired, the minimal
25 sequence requirement, i.e., a contiguous amino acid sequence of the shortest length, that is capable of delivering a protein. See, e.g., Sory et al (1994). Accordingly, preferred delivery signals of the present invention consists of at least the minimal sequence of
30 amino acids of a Yop effector protein that is capable of delivering a protein.

Further in accordance with the present invention, a second DNA sequence encoding a heterologous protein is fused in frame to the first DNA sequence in the instant vector for delivery into eukaryotic cells.

The term "heterologous protein" used herein refers to a protein other than a *Yersinia* Yop protein.

"Yop proteins" refer to *Yersinia* virulon proteins that are secreted, including the translocators and the effectors.

According to the present invention, "a heterologous protein" includes naturally occurring proteins or parts thereof. The term "part of a protein" includes a peptide or polypeptide fragment of a protein that is of sufficient length to be antigenic. Preferably, such a fragment consists of at least 8 or 9 contiguous amino acids of a protein. "A heterologous protein" as used in the present invention also includes artificially engineered proteins or parts thereof, such as fusion of two or more naturally occurring proteins or parts thereof, polyepitopes (in-frame fusion of two or more peptide epitopes) as exemplified by Thompson et al. (1995) in *Proc. Natl. Acad. Sci. USA* 92: 5845-5849.

The protein expressed from the fused first and second DNA sequences is also termed as a "fusion protein" or a "hybrid protein", i.e., a hybrid of *Yersinia* delivery signal and a heterologous protein.

There is no particular limitation in the heterologous protein that can be delivered. The present invention particularly contemplates proteins,

such as, e.g., known tumor associated proteins, known antigens of pathogens, and cytokines.

5 A "tumor associated protein" refers to a protein that is specifically expressed in tumors or expressed at an abnormal level in tumors relative to normal tissues. Such tumor associated proteins include, but are not limited to, members of the MAGE family, the BAGE family (such as BAGE-1), the DAGE/Prame family (such as DAGE-1), the GAGE family, 10 the RAGE family (such as RAGE-1), the SMAGE family, NAG, Tyrosinase, Melan-A/ MART-1, gp100, MUC-1, TAG-72, CA125, mutated proto-oncogenes such as p21ras, mutated tumor suppressor genes such as p53, tumor associated viral antigens (e.g., HPV16 E7), HOM-MEL-15 40, HOM-MEL-55, NY-COL-2, HOM-HD-397, HOM-RCC-1.14, HOM-HD-21, HOM-NSCLC-11, HOM-MEL-2.4, and HOM-TES-11. Members of the MAGE family include, but are not limited to, MAGE-1, MAGE-2, MAGE-11. Members of the GAGE family include, but are not limited to, GAGE-1, 20 GAGE-6. See, e.g., review by Van den Eynde and van der Bruggen (1997) in *Curr. Opin. Immunol.* 9:684-693, Sahin et al. (1997) in *Curr. Opin. Immunol.* 9:709-716, and Shawler et al. (1997). These proteins have been shown to associate with certain tumors such as 25 melanoma, lung cancer, prostate cancer, breast cancer, renal cancer and others.

A number of known antigens derived from pathogens can also be employed according to the present invention. Pathogens contemplated by the 30 present invention include viruses, bacteria, parasites and fungi. Specific examples of antigens

characteristic of a pathogen include the influenza virus nucleoprotein (residues 218-226, as set forth in F. et al. (1997) *J. Virol.* 71: 2715-2721) antigens from Sendai virus and lymphocytic choriomeningitis virus (see, An et al. (1997) *J. Virol.* 71: 2292-2302), the B1 protein of hepatitis C virus (Bruna-Romero et al. (1997) *Hepatology* 25: 470-477), the virus envelope glycoprotein gp 160 of HIV (Achour et al. (1996) *J. Virol.* 70: 6741-6750), amino acids 252-260 or the circumsporozoite protein of *Plasmodium berghei* (Allsopp et al. (1996) *Eur. J. Immunol.* 26: 1951-1958), the influenza A virus nucleoprotein (residues 366-374, Nomura et al. (1996) *J. Immunol. Methods* 193: 4149), the listeriolysin O protein of *Listeria monocytogenes* (residues 91-99, An et al. (1996) *Infect. Immun.* 64: 1685-1693), the E6 protein (residues 131-140, Gao et al. (1995) *J. Immunol.* 155: 5519-5526) and E7 protein (residues 21-28 and 48-55, Bauer et al. (1995) *Scand. J. Immunol.* 42: 317-323) of human papillomavirus type 16, the M2 protein of respiratory syncytial virus (residues 82-90 and 81-95, Hsu et al. (1995) *Immunology* 85: 347-350), the herpes simplex virus type 1 ribonucleotide reductase (see, Salvucci et al. (1995) *J. Gen. Virol.* 69: 1122-1131) and the rotavirus VP7 protein (see, Franco et al. (1993) *J. Gen. Virol.* 74: 2579-2586), *P. falciparum* antigens (causing malaria) and hepatitis B surface antigen (Gilbert et al. (1997) *Nature Biotech.* 15: 1280-1283).

Accordingly, sequences coding for the above-described proteins may be cloned into the present expression vector for delivery.

5 A number of coding sequences for small antigenic peptides can also be employed in the present invention. One skilled in the art can readily determine the length of the fragments required to produce immunogenic peptides. Alternatively, the skilled artisan can also use coding sequences for
10 peptides that are known to elicit specific T cell responses, such as tumor-associated antigenic peptides (TRAs) as disclosed by U.S. Patent No. 5,462,871, U.S. Patent No. 5,558,995, U.S. Patent No. 5,554,724, U.S. Patent No. 5,585,461, U.S. Patent No. 5,591,430, U.S.
15 Patent No. 5,554,506, U.S. Patent No. 5,487,974, U.S. Patent No. 5,530,096, U.S. Patent No. 5,519,117. Examples of TRAs are provided in Table 1. See also review by Van den Eynde and van der Bruggen (1997) and Shawler et al. (1997). Antigenic peptides of a
20 pathogen origin can also be used, such as those disclosed by Gilbert et al. (1997).

As described herein above, sequences coding for a full-length naturally occurring protein, a part of a naturally occurring protein, combinations of
25 parts of a naturally occurring protein, or combinations of different naturally occurring proteins or parts from different proteins, may all be employed in the present invention. For example, a sequence coding for multiple epitopes may be used, such as
30 those described by Thomson et al. (1995). Preferably, the second DNA sequence of the present expression

vector codes for at least one epitope of a protein. An "epitope" refers to a peptide of at least 8 or 9 amino acids.

5 Those skilled in the art are familiar with the techniques to make DNA fragments coding for a part of a protein, or link a DNA sequence encoding a part of one protein in frame to a DNA sequence encoding a part of another protein and the like.

10 The vectors of the instant invention may include other sequence elements such as a 3' termination sequence (including a stop codon and a poly A sequence), or a gene conferring a drug resistance which allows the selection of *Yersinia* transformants having received the instant vector.

15 The expression vectors of the present invention may be transformed by a number of known methods into *Yersinia*. For the purpose of the present invention, the methods of transformation for introducing an expression vector include, but are not limited to, electroporation, calcium phosphate mediated transformation, conjugation, or combinations thereof. For example, a vector can be transformed into a first bacteria strain by a standard electroporation procedure. Subsequently, such a
25 vector can be transferred from the first bacteria strain into *Yersinia* by conjugation, a process also called "mobilization". *Yersinia* transformant (i.e., *Yersinia* having taken up the vector) may be selected, e.g., with antibiotics. These techniques are well
30 known in the art. See, for example, Sory et al. (1994).

One preferred embodiment of the present invention is directed to a *Yersinia* of the above-described mutant *Yersinia* strain transformed with an expression vector for delivery of a heterologous protein as hereinabove described into a eukaryotic cell.

Accordingly, the present invention contemplates a method for delivering heterologous proteins as hereinabove described into eukaryotic cells.

The present invention contemplates a wide range of eukaryotic cells that may be targeted by the instant recombinant *Yersinia*.

By "target", is meant the extracellular adhesion of *Yersinia* to a eukaryotic cell.

In particular, the present invention contemplates antigen-presenting cells. "Antigen presenting cells" as referred herein express at least one class I or class II MHC determinant and may include those cells which are known as professional antigen-presenting cells such as macrophages, dendritic cells and B cells. Other professional antigen-presenting cells include monocytes, marginal zone Kupffer cells, microglia, Langerhans' cells, interdigitating dendritic cells, follicular dendritic cells, and T cells. Facultative antigen-presenting cells can also be used according to the present invention. Examples of facultative antigen-presenting cells include astrocytes, follicular cells, endothelium and fibroblasts. As used herein,

"antigen-presenting cells" encompass both professional and facultative types of antigen-presenting cells.

5 The antigen presenting cells can be isolated from tissue or blood (containing peripheral blood mononuclear cells) samples obtained from a mammal such as a human or rodent. Cell lines established from such samples may also be used. Procedures for establishing cell lines are well known in the art. Certain cell lines may be obtained directly from the
10 American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland, 20852-1776. Both normal and malignant cells may be employed.

15 In accordance with a preferred embodiment of the present invention, the MHC determinants expressed by the antigen presenting cell are compatible with those expressed by the mammal involved, and at least one of these MHC determinants is capable of presenting one or more antigenic epitopes derived from the protein being delivered.

20 One skilled in the art is also familiar with the methods for determining whether the MHC molecules expressed by the antigen presenting cell are compatible with those of the mammal subject involved, such as well known HLA-typing procedures. See general
25 teachings by Coligan et al. (1994) *Current Protocols in Immunology* John Wiley & Sons Inc: New York, New York.

30 Those skilled in the art are able, through the extensive teachings in the art, to determine the MHC molecule for presentation of a particular antigen. For example, U.S. Patent No. 5,405,940 teaches the

determination of HLA-A1 as the presenting molecule for a peptide of MAGE-1, EADPTGHSY; U.S. Patent No. 5,558,995 teaches the determination of HLA-Cw1601 for presenting another peptide of MAGE-1, SAYGEPRKL; U.S. Patent No. 5,530,096 teaches the determination of HLA-A2 as the presenting molecule for a peptide of Tyrosinase, MLLAVLYCL. In the event the eukaryotic cells being targeted do not express a desired HLA or MHC molecule, the gene encoding such molecule may be introduced into the eukaryotic cells by well known transformation or transfection procedures.

Further in accordance with the present invention, the delivery of a protein can be achieved by contacting a eukaryotic cell with a recombinant *Yersinia* under appropriate conditions. Various references and techniques are conventionally available for those skilled in the art regarding the conditions for inducing the expression and translocation of virulon genes, including the desired temperature, Ca++ concentration, manners in which *Yersinia* and target cells are mixed, and the like. See, for example, Cornelis, *Cross talk between Yersinia and eukaryotic cells*, Society for General Microbiology Symposium, 55; MocRAE, SAUNDERS, SMYTH, STOW (eds), *Molecular aspects of host-pathoge interactions*, Cambridge University Press, 1997. The conditions may vary depending on the type of eukaryotic cells to be targeted, e.g., the conditions for targeting human epithelial carcinoma Hela cells (Sory et al. (1994)); the conditions for targeting mouse thymoma or melanoma cells (Starnbach et al. (1994) *J. Immunol.* 153: 1603); the conditions

for targeting mouse macrophages (Boland et al. (1996)). Such variations can be addressed by those skilled in the art using conventional techniques.

Those skilled in the art can also use a number of assays to determine whether the delivery of a fusion protein is successful. For example, the fusion protein may be labeled with an isotope or an immunofluoresceine, or detected by a immunofluoresceine conjugated antibody, as disclosed by Rosqvist et al. (1994) *EMBO J.* 13: 964. The determination can also be based on the enzymatic activity of the protein being delivered, e.g., the assay described by Sory et al. (1994). The determination can also be based on the antigenicity of the protein being delivered. For example, the delivery of a MAGE-1 protein into EBV-transformed human B cells can be detected by the recognition of such targeted B cells by CTL cells specific for MAGE-1 epitopes. Such CTL recognition, in turn, may be detected by a number of assays including assaying the secretion of IFN- γ from the activated CTLs or Cr⁵¹ release from lysed target cells. Methods such as Western-blot analysis using antibodies specific against the protein being delivered, PCR in situ hybridization, or ELISPOT (Mabtech AB, Sweden) may also be employed for such determination. See, e.g., W. Herr et al. (1997) *J. Immunol. Methods* 203: 141-152 and W. Herr et al. (1996) *J. Immunol. Methods* 191: 131-142.

In a further aspect of the present invention, recombinant *Yersinia* capable of delivering

proteins to antigen-presenting cells are employed for inducing an immune response. Accordingly, the present invention contemplates immunogenic compositions and methods for inducing specific immune responses using
5 the instant recombinant *Yersinia* as described hereinabove.

The immune responses contemplated by the present invention include cellular immune responses (mediated primarily by T cells) and humoral immune
10 responses (mediated primarily by antibodies). Janeway and Travers teach in general these immune response. (Janeway and Travers (1996) *Immunology, The Immune System in Health and Disease* 2nd ed. Garland Publishing, Inc.: New York, New York, and London,
15 England.) (See also, review by O. Tureci et al. (1997) *Molecular Medicine Today* 3(8): 342-349.

According to this aspect of the present invention, the immune responses induced with recombinant *Yersinia* can be utilized in a number of
20 regimes for diagnostic or therapeutic use. For example, recombinant *Yersinia* can be employed in an *in vitro* procedure for monitoring the efficacy of a vaccination therapy in a mammal such as a human or rodent. In this regime, certain antigen presenting
25 cells (e.g., dendritic cells) are taken from a subject being vaccinated with immunogenic compositions, e.g., a particular antigen. Such antigen presenting cells are then contacted with recombinant *Yersinia* capable of delivering the antigen which is used for
30 vaccination. Subsequently, peripheral blood lymphocytes taken from the same subject (i.e.,

autologous PBLs) are added, preferably in combination with cytokines such as IL-2, to the mixture of antigen presenting cells and *Yersinia*. The efficacy of the vaccination can be assessed after priming and then
5 after successive boosts by the presence of CTLs or antibodies that are specific for the relevant antigen. The presence of specific CTLs can be detected using standard assays such as an assay for Cr⁵¹ release or for the secretion of IFN-gamma. The presence of
10 specific antibodies can be detected by assays such as ELISA using the antigens which are immobilized on a culture plate, or a standard proliferation assay for T-helper cells.

Recombinant *Yersinia* can also be employed in
15 an *ex vivo* regime for inducing CTLs specific for a protein. The procedure to develop such specific CTLs *in vitro* is known in the art, e.g., as disclosed by the United States Patent No. 5,342,774. Briefly, a blood sample containing T cell precursors is taken
20 from a mammal. PBLs are purified from such blood sample and are incubated with stimulator cells expressing an antigenic epitope in the context of an MHC molecule. CTLs specific for such epitope produced can be detected by assays such as an assay for Cr⁵¹
25 release or secretion of IFN-gamma.

According to the present invention, a mixture of a recombinant *Yersinia* and an antigen presenting cell can be used as the "stimulator cell" in such an *in vitro* procedure for producing CTLs
30 specific for the protein being delivered. The MHC determinants expressed by the antigen presenting cell

used are compatible with those expressed by the mammal from which PBLs are isolated, and at least one of these MHC molecules is capable of presenting, to T cells, one or more epitopes derived from the protein being delivered. CTL cells generated as such can be administered, in a therapy regimen of adoptive transfer, to a mammal a pathological condition characterized by an abnormal expression of the protein used in the delivery system. See teachings by Greenberg (1986) *J. Immunol.* 136 (5): 1917; Riddel et al. (1992) *Science* 257: 238; Lynch et al. (1991) *Eur. J. Immunol.* 21: 1403; and Kast et al. (1989) *Cell* 59: 603 for adoptive transfer. CTLs, by lysing the cells abnormally expressing such antigens, can alleviate or treat the pathological condition at issue such as a tumor, an infection with a parasite or a virus.

Accordingly, the present invention contemplates methods and compositions for treating pathological conditions. The pathological conditions contemplated by the present invention include tumors and infections by pathogens such as bacteria, parasites, fungus or virus.

By "treating", is meant alleviating or inhibiting a pathological condition, e.g., inhibiting tumor growth or metastasis, reducing the size of tumor, or diminishing symptoms of a pathogen infection.

The recombinant *Yersinia* of the present invention can also be employed *in vivo*, i.e., introducing recombinant *Yersinia* into a mammal, such as a human or rodent subject.

For in vivo use of recombinant *Yersinia*, the safety can be tested in animals beforehand. In this case, the recombinant *Yersinia* may be administered to the animal orally or directly into the stomach. The animals may be sacrificed a few days (1-3 days) after the administration of the recombinant *Yersinia*. The intestines are washed and the Peyer patches or the faeces can be examined for viable *Yersinia*. See, e.g., Sory et al. (1992) *Infect. Immun.* 60: 3830-3836. The recombinant *Yersinia* may also be administered to the animal by intraperitoneal injection. Organs of sacrificed animals such as spleen and liver can be examined for the presence of intracellular *Yersinia*, an indication of insufficient safety. Intracellular *Yersinia* may be detected by e.g., cultivating cell extracts on solid medium. See teachings by Sory et al. (1988) *Microb. Pathogen* 4: 431-442.

A safe recombinant *Yersinia* may be employed in an immunogenic composition to induce an immune response for treating various pathological conditions in mammals. The pathological conditions contemplated by the present invention include tumors and pathogen infections, as disclosed herein.

The immunogenic compositions can include, in addition to a recombinant *Yersinia*, other substances such as cytokines, adjuvants and pharmaceutically acceptable carriers. Cytokines can also be included in such immunogenic compositions using additional recombinant *Yersinia* of the present invention capable of delivering a cytokine, for example.

These immunogenic compositions may be administered to the subject in any convenient manner, such as orally, intraperitoneally, intravenously or subcutaneously. Specific immune responses induced by
5 such compositions can lead to the CTL-mediated or antibody-mediated killing of the pathogens or cells with abnormal expression of a relevant antigen, thus alleviating the relevant pathological condition.

The present invention is further illustrated
10 by the following examples.

All the publications mentioned in the present disclosure are incorporated herein by reference. The terms and expressions which have been employed in the present disclosure are used as terms
15 of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, it being recognized that various modifications are possible within the
20 scope of the invention.

Example 1**Bacterial Strains, Plasmids and Growth Conditions**

The work was carried out with

5 *Y. enterocolitica* E40(pYV40) (see, M.P. Sory et al. (1995) "Identification of the YopE and YopH domains required for secretion and internalization into the cytosol of macrophages, using the *cyaA* gene fusion approach" *Proc. Nat'l Acad. Sci. USA* 92: 11998-12002), its isogeneic ampicillin sensitive derivative

10 MRS40(pYV40) (see, M.R. Sarker et al., and their various non-polar mutants. Plasmids are listed in Table 1. Bacteria were grown in Brain Heart Infusion (BHI) (Difco, Destroit, Michigan). After overnight

15 preculture, bacteria were diluted 1/20 in fresh BHI, allowed to grow for 30 minutes at room temperature, and synthesis of the Yop virulon was induced by incubation for 150 minutes at 37°C before infection.

Table 1: Exemplary Antigens

	Gene	MHC	Peptide	Position	SEQ ID NO:
5	MAGE-1	HLA-A1	EADPTGHSY	161-169	1
		HLA-Cw16	SAYGEPRKL	230-238	2
	MAGE-3	HLA-A1	EVDPIGHLV	168-176	3
		HLA-A2	FLWGPRALV	271-279	4
		HLA-B44	MEVDPIGHLV	167-176	5
10	BAGE	HLA-Cw16	AARAVFLAL	2-10	6
	GAGE-1,2	HLA-Cw16	YRPRPRRY	9-16	7
	RAGE	HLA-B7	SPSSNRIRNT	11-20	8
	GnT-V	HLA-A2	VLPDVFIRC (V)	2-10/11	9
	MUM-1	HLA-B44	EEKLIVVLF	exon 2/ intron	10
15			EEKLSVVLF (wild type)		11
	CDK4	HLA-A2	ACDPHSGHFV	23-32	12
			ARDPHSGHFV (wild type)		13
	β -catenin	HLA-A24	SYLDSGIHF	29-37	14
			SYLDSGIHS (wild type)		15
20	Tyrosinase	HLA-A2	MLLAVLYCL	1-9	16
		HLA-A2	YMNGTMSQV	369-377	17
		HLA-A2	YMDGTMSQV	369-377	18
		HLA-A24	AFLPWHLRF	206-214	19

5		HLA-B44	SEIWRDIDF	192-200	20
		HLA-B44	YEIWRDIDF	192-200	21
		HLA-DR4	QNILLSNAPLGPO FP	56-70	22
		HLA-DR4	DYSYLQSDPDSPF QD	448-462	23
	Melan-A ^{MART-1}	HLA-A2	(E) AAGIGILTV	26/27-35	24
		HLA-A2	ILTVILGVL	32-40	25
	gp100 ^{Pmel117}	HLA-A2	KTWGQYWQV	154-162	26
		HLA-A2	ITDQVPFSV	209-217	27
		HLA-A2	YLEPGPVTA	280-288	28
		HLA-A2	LLDGTATLRL	457-466	29
		HLA-A2	VLYRYGSFSV	476-485	30
		DAGE	HLA-A24	LYVDSLFFL	301-309

10	MAGE-6	HLA-Cw16	KISGGPRISYPL	292-303	32
----	--------	----------	--------------	---------	----

Example 2

Construction of the Polymutant Strains

To construct the *yopHOPEM* polymutant strain,
5 the *yopE*, *yopH*, *yopO*, *yopM* and *yopP* genes were
successively knocked out by allelic exchange in the
MRS40 strain using the suicide vectors pMRS101 and
pKNG101. See, K. Kaniga et al. (1991) "A wide-host
range suicide vector for improving reverse genetics in
10 gram-negative bacteria: inactivation of the *blaA* gene
of *Yersinia enterocolitica*" *Gene* 109: 137-141 and
M.R. Sarker et al. (1997) "An improved version of
suicide vector pKNG101 for gene replacement in Gram-
negative bacteria" *Mol. Microbiol.* 23: 409-411. The
15 various deletions are described in Table 2 in the
"suicide vectors and mutators" section. The *YopE* gene
was first mutated using the mutator pPW52 (see, P.
Wattiau et al. (1993) "SycE, a chaperone-like protein
of *Yersinia enterocolitica* involved in the secretion
20 of *YopE*" *Mol. Microbiol.* 8: 123-131), giving strain
MRS40(pAB4052). Mutation of the *YopH* gene in this
strain with the mutator pAB31 (see, S.D. Mills et al.
(1997) "*Yersinia enterocolitica* induces apoptosis in
macrophages by a process requiring functional type III
25 secretion and translocation mechanisms and involving
YopP, presumably acting as an effector protein" *Proc.*
Natl. Acad. Sci. USA 94: 12638-12643) gave the double
yopEH mutant MRS40(pAB404). The triple *yopEHO* mutant
MRS40(pAB405) was then obtained by allelic exchange
30 with the mutator pAB34 (see, S.D. Mills et al., 1997).
The *YopP* gene was then mutated with mutator pMSK7 (see

S.D. Mills et al. (1997)), leading to the *yopEHOP* mutant MRS40(pMSK46). The *yopHOPEM* strain MRS40(pABL403) was finally obtained by allelic exchange with the *yopM* mutator pAB38 (see, S.D. Mills et al., 1997).

5

Table 2: Plasmids

Plasmids	Relevant Characteristics	References
pYV		
5 pABL403	pYV40 yopE ₂₁ , yopH Δ ¹⁻³⁵² yopO Δ ⁶⁵⁻⁵⁵⁸ , yopP ₂₃ , yopM ₂₃	see Example 2 of the present specification
	Suicide Vectors and mutators	
pKNG101	ori ^{R6K} sac ^{BR+} on ^{TRK2} str ^{AB+}	K. Kaniga et al. (1991) <i>Gene</i> 109: 137-141.
pMRS101	ori ^{R6K} sac ^{BR+} on ^{TRK2} str ^{AB+} ori ^{ColE1} bla ⁺	M.R. Sarker and G.R. Cornelis (1997) <i>Mol.</i> <i>Microbiol.</i> 23: 409-411.
pAB31	pMRS101 yopH Δ ₁₋₃₅₂ ⁺	S.D. Mills et al. (1997) <i>Proc. Natl. Acad. Sci.</i> <i>USA</i> 94: 12638-12643.
10 pAB34	pMRS101 yopO Δ ₆₅₋₅₅₈ ⁺	S.D. Mills et al. (1997)
pAB38	pMRS101 yopM ₂₃ ⁺	S.D. Mills et al. (1997)
pMSK7	pMRS101 yopP ₂₃ ⁺	S.D. Mills et al. (1997)
pPW52	pKNG101 yopE ₂₁ ⁺	P. Waattiau and G.R. Cornelis (1993) <i>Mol.</i> <i>Microbiol.</i> 8: 123-131.

Example 3

Construction of a Plasmid Encoding YopE₁₃₀-MAGE-1 and Introduction of this Plasmid into *Yersinia*

5 The sequence encoding protein MAGE-1 was
inserted in frame with a sequence encoding a truncated
YopE, YopE₁₃₀, containing the first 130 amino acids of
YopE. Such a plasmid is graphically depicted in
Figure 1.

10 The open reading frame of MAGE-1 was
amplified by PCR using a MAGE-1 cDNA cloned in
pcDNA1/Amp (Invitrogen, Carlsbad, California) as
template. The upstream primer,
AAACTGCAGATGTCTCTTGAGCAGAGGAGTC, consisted of the
15 first nucleotides of the open reading frame of MAGE-1
preceded by a PstI site. The downstream primer,
AAACTGCAGTCAGACTCCCTCTTCCTCCTC, consisted of
nucleotides complementary to the last nucleotides of
the open reading frame of MAGE-1 followed by a PstI
20 site. The PCR product was digested with PstI and
inserted in frame with the truncated YopE at the PstI
site of vector pMS111 (see, Sory et al. (1994)
Molecular Microbiology 14: 583-594). pMS111-MAGE-1
was electroporated in bacteria strain DH5αF'IQ. DNA
25 was extracted from some clones and the DNA of a
positive recombinant clone was electroporated in
bacteria strain SM10. After mobilization of pMS111
from SM10 in *Yersinia* MRS40 (pABL403), recombinant
clones were then selected on agar-containing medium,
30 supplemented with nalidixic acid, sodium-arsenite and
chloramphenicol. MRS40 is an isogeneic derivative of

E40 sensitive to ampicillin (see, Sory et al. (1995)
Proc. Natl. Acad. Sci. USA 92: 11998-12002).

Example 4

Targeting EBV-Transformed B Cells

One colony of *Yersinia* MRS40 (pABL403)
5 containing pMS111-MAGE-1 was then grown overnight at
28°C in LB medium supplemented with nalidixic acid,
sodium m-arsenite and chloramphenicol. The overnight
culture was diluted in fresh medium in order to obtain
an OD (optical density) of 0.2. The fresh culture was
10 amplified at 28°C for approximately 2 hours. The
bacteria were washed in 0.9% NaCl and resuspended at
10⁸ bacteria per ml in 0.9% NaCl. 50,000 EBV-
transformed HLA-A1⁺ B cells (KASOII-EBV) were placed
in microwells (96 wells round-bottomed) and pelleted
15 by centrifugation. The supernatant was discarded and
various dilutions of bacteria were added in 100 µl of
complete RPMI 1640 (culture media was supplemented
with 10% FCS and with L-arginine (116 mg/ml), L-
asparagine (36 mg/ml), L-glutamine (216 mg/ml). Two
20 hours after infection, gentamicin (30 µg/ml) was added
for the next two hours, and the cells were finally
washed three times.

As a negative control, the same cells were
also infected with *Yersinia* MRS40 (pABL403) containing
25 pMS621, a plasmid which encodes only the truncated
YopE, i.e., YopE₁₃₀.

Example 5

Recognition of Targeted B Cells by MZ2-CTL 82/30

MZ2-CTL 82/30 are specific for the MAGE-1
5 peptide EADPTGHSY which is presented by HLA-A1 (U.S.
Patent No. 5,342,774). 5000 MZ2-CTL 82/30 cells were
added in each microwell containing the *Yersinia* in a
final volume of 100 μ l of Iscove's complete medium
(culture medium was supplemented with 10% human serum,
10 L-arginine (116 mg/ml), L-asparagine (36 mg/ml), L-
glutamine (216 mg/ml), streptomycin (0.1 mg/ml),
penicillin (200 U/ml), IL-2 (25 U/ml) and gentamicin
(15 μ g/ml). After overnight incubation, the presence
of IFN-gamma (that is produced by CTL upon activation)
15 in the supernatant of the co-culture was tested in a
standard ELISA assay (Biosource, Fleurus, Belgium).
Figure 2A graphically depicts such a procedure.

As indicated in Figure 2B, the HLA-A1⁺ B
cells infected with *Yersinia* encoding YopE₁₃₀-MAGE-1
20 were recognized by the CTL 82/30, while the same cells
infected with the control plasmid YopE₁₃₀ were not.
The optimal concentration of bacteria is around
1,000,000 per microwell.

WHAT IS CLAIMED IS:

1 1. A mutant *Yersinia* strain comprising at
2 least one mutation in at least one *Yersinia* effector-
3 encoding gene, whereby said mutant *Yersinia* strain is
4 deficient in the production of at least one functional
5 effector protein.

1 2. The mutant *Yersinia* strain according to
2 claim 1, wherein said effector encoding gene is
3 selected from the group consisting of *YopE*, *YopH*,
4 *YopO*, *YopM* and *YopP* of *Y. enterocolitica*; and *YopE*,
5 *YopH*, *YpkA*, *YopM* and *YopJ* of *Y. pseudotuberculosis*.

1 3. The mutant *Yersinia* strain according to
2 claim 1, wherein said mutation is a mutation of the
3 promoter sequence of said effector gene.

1 4. The mutant *Yersinia* strain according to
2 claim 1, wherein said mutation is a mutation of the
3 coding sequence of said effector gene.

1 5. A quintuple mutant *Yersinia* strain
2 having the designation of *Y. enterocolitica yopEHOMP*
3 or *Y. pseudotuberculosis yopEHAOJ*.

1 6. The quintuple mutant *Yersinia* strain
2 according to claim 5, having the designation of
3 *Yersinia enterocolitica* MRS40 (pABL403).

1 7. An expression vector for delivering a
2 heterologous protein into a eukaryotic cell, which
3 comprises in the 5' to 3' direction:
4 a promoter from a *Yersinia* virulon gene;
5 a first DNA sequence encoding a delivery
6 signal from a *Yersinia* effector protein, operably
7 linked to said promoter; and
8 a second DNA sequence coding for said
9 heterologous protein, fused in frame to the 3' end of
10 said first DNA sequence.

1 8. The expression vector of claim 7,
2 wherein said *Yersinia* virulon gene is a *Yersinia*
3 effector-encoding gene.

1 9. The expression vector of claim 8,
2 wherein said effector-encoding gene is selected from
3 the group consisting of *YopE*, *YopH*, *YopO*, *YopM* and
4 *YopP* of *Y. enterocolitica*; and *YopE*, *YopH*, *YpkA*, *YopM*
5 and *YopJ* of *Y. pseudotuberculosis*.

1 10. The expression vector of claim 9,
2 wherein said effector-encoding gene is *Y.*
3 *enterocolitica* of *YopE*.

1 11. The expression vector of claim 7,
2 wherein said effector protein is selected from the
3 group consisting of *YopE*, *YopH*, *YopO*, *YopM* and *YopP* of
4 *Yersinia enterocolitica*; and *YopE*, *YopH*, *YpkA*, *YopM*
5 and *YopJ* of *Y. pseudotuberculosis*.

1 12. The expression vector of claim 11,
2 wherein said effector protein is one of *Yersinia*
3 *enterocolitica* YopE or *Y. pseudotuberculosis* YopE.

1 13. The expression vector of claim 7,
2 wherein said delivery signal is *Y. enterocolitica*
3 YopE₁₃₀.

1 14. The expression vector of claim 7,
2 wherein said heterologous protein comprises at least
3 one epitope of a naturally occurring protein.

1 15. The expression vector of claim 14,
2 wherein said naturally occurring protein is a tumor
3 associated protein or a pathogen antigen.

1 16. The expression vector of claim 15,
2 wherein said tumor associated protein is selected from
3 the group consisting of members of the MAGE family,
4 the BAGE family, the DAGE/Prame family, the GAGE
5 family, the RAGE family, the SMAGE family, NAG,
6 Tyrosinase, Melan-A/MART-1, gp100, MUC-1, TAG-72,
7 CA125, p21ras, p53, HPV16 E7, HOM-MEL-40, HOM-MEL-55,
8 NY-COL-2, HOM-HD-397, HOM-RCC-1.14, HOM-HD-21, HOM-
9 NSCLC-11, HOM-MEL-2.4, and HOM-TES-11.

1 17. The expression vector of claim 16,
2 wherein said tumor-associated protein is MAGE-1.

1 18. A *Yersinia* of a *Yersinia* mutant strain
2 of any one of claims 1-6 for delivery of a

heterologous protein into a eukaryotic cell, wherein said *Yersinia* is transformed with an expression vector which comprises in the 5' to 3' direction:

a promoter from a *Yersinia* virulon gene;
a first DNA sequence encoding a delivery signal from a *Yersinia* effector protein, operably linked to said promoter; and
a second DNA sequence coding for said heterologous protein, fused in frame to the 3' end of said first DNA sequence.

19. The *Yersinia* according to claim 18, wherein said *Yersinia* virulon gene is a *Yersinia* effector-encoding gene.

20. The *Yersinia* according to claim 19, wherein said effector-encoding gene is selected from the group consisting of *YopE*, *YopH*, *YopO*, *YopM* and *YopP* of *Y. enterocolitica*; and *YopE*, *YopH*, *YpkA*, *YopM* and *YopJ* of *Y. pseudotuberculosis*.

21. The *Yersinia* according to claim 20, wherein said effector-encoding gene is *Y. enterocolitica YopE*.

22. The *Yersinia* according to claim 18, wherein said effector protein selected from the group consisting of *YopE*, *YopH*, *YopO*, *YopM* and *YopP* of *Yersinia enterocolitica*; and *YopE*, *YopH*, *YpkA*, *YopM* and *YopJ* of *Y. pseudotuberculosis*.

1 23. The *Yersinia* according to claim 22,
2 wherein said effector protein is one of *Yersinia*
3 *enterocolitica*'s YopE or *Y. pseudotuberculosis*'s YopE.

1 24. The *Yersinia* according to claim 18,
2 wherein said delivery signal is *Y. enterocolitica*
3 YopE₁₃₀.

1 25. The *Yersinia* according to claim 18,
2 wherein said heterologous protein comprises at least
3 one epitope of a naturally occurring protein.

1 26. The *Yersinia* according to claim 25,
2 wherein said naturally occurring protein is a tumor-
3 associated protein or a pathogen antigen.

1 27. The *Yersinia* according to claim 26,
2 wherein said tumor-associated protein is selected from
3 the group consisting of members of the MAGE family,
4 the BAGE family, the DAGE/Prame family, the GAGE
5 family, the RAGE family, the SMAGE family, NAG,
6 Tyrosinase, Melan-A/MART-1, gp100, MUC-1, TAG-72,
7 CA125, p21ras, p53, HPV16 E7, HOM-MEL-40, HOM-MEL-55,
8 NY-COL-2, HOM-HD-397, HOM-RCC-1.14, HOM-HD-21, HOM-
9 NSCLC-11, HOM-MEL-2.4, and HOM-TES-11.

1 28. The *Yersinia* according to claim 27,
2 wherein said tumor-associated protein is MAGE-1.

1 29. A method for delivering a heterologous
2 protein into a eukaryotic cell, comprising contacting

3 said eukaryotic cell with a *Yersinia* of a mutant
4 strain of claim 1 transformed with an expression
5 vector characterized by in 5' to 3' direction:
6 a promoter from a *Yersinia* virulon gene;
1 a first DNA sequence encoding a delivery
2 signal from a *Yersinia* effector protein, operably
3 linked to said promoter; and
4 a second DNA sequence coding for said
5 heterologous protein, fused in frame to the 3' end of
6 said first DNA sequence.

1 30. The method of claim 29, wherein said
2 eukaryotic cell is an antigen presenting cell.

1 31. The method of claim 30, wherein said
2 antigen presenting cell is selected from the group
3 consisting of a B cell, a macrophage, a dendritic
4 cell, a monocyte, a follicular cell, and a fibroblast.

1 32. The method of claim 30, wherein said
2 antigen presenting cell expresses an MHC molecule
3 capable of presenting one or more epitopes derived
4 from said heterologous protein.

1 33. The method of claim 29, wherein said
2 effector protein is selected from the group consisting
3 of YopE, YopH, YopO, YopM and YopP of *Yersinia*
4 *enterocolitica*; and YopE, YopH, YpkA, YopM and YopJ of
5 *Y. pseudotuberculosis*.

1 34. The method of claim 33, wherein said
2 effector protein is one of *Yersinia enterocolitica*
3 yopE or *Y. pseudotuberculosis* YopE.

1 35. The method of claim 29, wherein said
2 effector protein is YopE₁₃₀ of *Yersinia enterocolitica*.

1 36. The method of claim 29, wherein said
2 heterologous protein comprises at least one epitope of
3 a naturally occurring protein.

1 37. A *Yersinia* according to claim 36,
2 wherein said naturally occurring protein is a tumor
3 associated protein or a pathogen antigen.

1 38. The expression vector of claim 37,
2 wherein said tumor associated protein is selected from
3 the group consisting of members of the MAGE family,
4 the BAGE family, the DAGE/Prame family, the GAGE
5 family, the RAGE family, the SMAGE family, NAG,
6 Tyrosinase, Melan-A/MART-1, gp100, MUC-1, TAG-72,
7 CA125, p21ras, p53, HPV16 E7, HOM-MEL-40, HOM-MEL-55,
8 NY-COL-2, HOM-HD-397, HOM-RCC-1.14, HOM-HD-21, HOM-
9 NSCLC-11, HOM-MEL-2.4, and HOM-TES-11.

1 39. The method of claim 38, wherein said
2 tumor-associated protein is MAGE-1.

1 40. The method of claim 29, wherein said
2 *Yersinia* virulon gene is a *Yersinia* effector-encoding
3 gene.

1 41. The method of claim 40, wherein said
2 effector-encoding gene is selected from the group
3 consisting of *YopE*, *YopH*, *YopO*, *YopM* and *YopP* of *Y.*
4 *enterocolitica*; and *YopE*, *YopH*, *YpkA*, *YopM* and *YopJ* of
5 *Y. pseudotuberculosis*.

1 42. The method of claim 41, wherein said
2 effector-encoding gene is *YopE* of *Y. enterocolitica*.

1 43. A method for inducing an immune
2 response specific for a heterologous protein,
3 comprising the steps of:

4 (a) selecting an antigen presenting cell
5 expressing an MHC molecule capable of presenting at
6 least one epitope of said heterologous protein;

7 (b) forming a cell mixture by contacting
8 said antigen presenting cell with a *Yersinia* of a
9 mutant *Yersinia* strain of claim 1 transformed with an
10 expression vector thereby delivering said heterologous
11 protein into said antigen presenting cell, wherein
12 said expression vector is characterized by in 5' to 3'
13 direction:

14 a promoter from a *Yersinia* virulon gene;
15 a first DNA sequence encoding a delivery
16 signal from a *Yersinia* effector protein, operably
17 linked to said promoter;

18 a second DNA sequence coding for said
19 heterologous protein, fused in frame to the 3' end of
20 said first DNA sequence; and

21 (c) contacting a sample containing
22 peripheral blood lymphocytes taken from a subject,

23 with the cell mixture formed in step (b) thereby
24 inducing an immune response specific for said
25 heterologous protein.

1 44. The method of claim 43, wherein said
2 epitope of is from a tumor associated protein.

1 45. The method of Claim 44, wherein said
2 tumor associated protein is selected from the group
3 consisting of members of the MAGE family, the BAGE
4 family, the DAGE/Prame family, the GAGE family, the
5 RAGE family, the SMAGE family, NAG, Tyrosinase, Melan-
6 A/MART-1, gp100, MUC-1, TAG-72, CA125, p21ras, p53,
7 HPV16 E7, HOM-MEL-40, HOM-MEL-55, NY-COL-2, HOM-HD-397,
8 HOM-RCC-1.14, HOM-HD-21, HOM-NSCLC-11, HOM-MEL-2.4,
9 and HOM-TES-11.

1 46. The method of claim 45, wherein said
2 tumor associated protein is MAGE-1.

1 47. The method of claim 46, wherein said
2 epitope is from MAGE-1 and said MHC molecule is HLA-
3 A1.

1 48. An immunogenic composition, comprising
2 a recombinant *Yersinia* according to claim 18.

1 49. A method of inducing a CTL response
2 specific for a heterologous protein in a subject in
3 need of such response, comprising the steps of:

1 (a) obtaining from said subject an antigen
2 presenting cell expressing an MHC molecule;

3 (b) forming a cell mixture by contacting
4 said antigen presenting cell with a *Yersinia* of a
5 mutant *Yersinia* strain of claim 1 transformed with an
6 expression vector, wherein said expression vector is
7 characterized by in 5' to 3' direction:

8 a promoter from a *Yersinia* virulon gene;

9 a first DNA sequence encoding a delivery
10 signal from a yersinia effector protein, operably
11 linked to said promoter; and

12 a second DNA sequence fused in frame to the
13 3' end of said first DNA sequence, wherein said second
14 DNA sequence codes for at least one epitope of said
15 heterologous protein which is presented by said MHC
16 molecule of said antigen presenting cell;

17 (c) contacting a sample containing
18 peripheral blood lymphocytes taken from said subject,
19 with the cell mixture formed in step (b), thereby
20 producing CTLs specific for said heterologous protein;
21 and

22 (d) administering CTLs produced in step (c)
23 to said subject thereby inducing a CTL response
24 specific for said heterologous protein in said
25 subject.

1 50. A method for determining the efficacy
2 of a vaccination regimen in a subject, wherein said
3 subject is vaccinated with an antigen, comprising the
4 steps of:

1 (a) obtaining from said subject an antigen
2 presenting cell expressing an MHC molecule;

3 (b) forming a cell mixture by contacting
4 said antigen presenting cell with a *Yersinia* of a
5 mutant *Yersinia* strain of claim 1 transformed with an
6 expression vector, wherein said expression vector is
7 characterized by in 5' to 3' direction:


8 a promoter from a *Yersinia* virulon gene;

9 a first DNA sequence encoding a delivery
10 signal from a yersinia effector protein, operably
11 linked to said promoter; and

12 a second DNA sequence fused in frame to the
13 3' end of said first DNA sequence, wherein said second
14 DNA sequence codes for at least one epitope of said
15 antigen which is presented by said MHC molecule of
16 said antigen presenting cell;

17 (c) contacting a sample containing
18 peripheral blood lymphocytes taken from said subject,
19 with the cell mixture formed in step (b), and assaying
20 the presence of an immune response specific for said
21 antigen thereby determining the efficacy of said
22 vaccination regimen.

1 51. A method for treating a pathological
2 disorder in a subject, comprising administering the
3 yersinia of claim 18 to said subject, wherein the
4 heterologous protein elicits an immune response
5 specific to said pathological disorder.



Anti-MAGE-1.A1 CTL recognize HLA-A1 cells incubated with
Yersinia which produces a YopE130.MAGE-1 fusion protein




FIGURE 2A




FIGURE 2B

3/7

```

1   aaaaatggcc aaaaactttc aatggtagaa gagctaaatt tggataagta acgcataaaa
61  attttcgacg aaaaactata tatatatata tatttaatat gtatgggtttc atttgcaatg
121 aaaaaaccga taataaagat attttcagaa aggcattcaa tatgtttata aacccaagaa
181 atgtatctaa tacttttttg caagaacccat tacgtcattc ttctgattta actgagatgc
241 cagttgaggc agaaaatgtt aaatctaagg ctgaatatta taatgcatgg tcggaatggg
301 aacgaaatgc ccctccgggg aatgggtgaac agaggggaat ggcgggtttca aggttacgcg
361 attgcctgga ccgacaagcc catgagctag aactaaataa tctggggctg agttcctttgc
421 cggaattacc tccgcattta gagagttag tggcgtcatg taattctctt acagaattac
481 cggaattgcc gcagagcctg aaatcacttc aagttgataa taacaatctg aaggcattat
541 ccgatttacc tcctttactg gaatathtag gtgccgctaa taatcagctg gaagaattac
601 cagagttgca aaactcgtcc ttcttgacat ctattgatgt tgataacaat tcactgaaaa
661 cattacctga tttacctcct tcactggaat ttcttgctgc tggtaataat cagctggaag
721 aattgtcaga gttgcaaaac ttgcccttct tgactgcgat ttatgctgat aacaattcac
781 tgaaaacatt acccgattta ccccttccc tgaaaacact taatgtcaga gaaaattatt
841 taactgatct gccagaatta ccgcagagtt taaccttctt agatgtttct gataatattt
901 tttctggatt atcggaattg ccaccaaact tgtataatct caatgcatcc agcaatgaaa
961 taagatcttt atgcgattta cccctttcac tggtagaact tgatgtcaga gataatcagt
1021 tgatcgaact gccagcggtta cctccacgct tagaacgttt aatcgcttca tttaatcatc
1081 ttgctgaagt acctgaattg ccgcaaaacc tgaaactgct ccacgtagag tacaacgctc
1141 tgagagagtt tcccgatata cctgagtcag tggagatct tccgatggac tctgaacgtg
1201 taattgatcc atatgaattt gctcatgaga ctatagacaa acttgaagat gatgtatttg
1261 agtagtgccg aagagcggtc ataattctgc gtcacgttaa aatatcatta caacgtaatc
1321 actttatcga

```

FIGURE 3

4/7

```

1   gaattcccca actttgacac cgataaccgg ttcaatagta tctggaatag acagcgaaag
61  ttgttgaaat aattgagtga tagcttggtc aaatgaatac atttgatctc ctaatagtta
121 gataaaatat caacttaacc aaagcactct cggcagacca tcaatttttag cctataatth
181 ttagttttta ttttgtctaa tataacaaca aaaacagcag cggtttttta tataaccacc
241 ggctattttc ccactaagat aaccttggtt taatagccaa gggaataaat agtcatgaaa
301 atatcatcat ttatttctac atcactgccc ctgccggcat cagtgtcagg atctagcagc
361 gtaggagaaa tgtctgggag ctgagttctc cagcaaaaaa gtgatcaata tgcaacaat
421 ctggccgggc gcactgaaag ccctcagggt tccagcttag ccagccgtat cattgagagg
481 ttatcatcaa tggcccactc tgtgattgga tttatccaac gcatgttctc ggaggggagc
541 cataaaccgg tggtgacacc agcactcacg cctgcacaaa tgccaagccc tacgtctttc
601 agtgatagta tcaagcaact tgctgctgag acgctgcaa aatacatgca gcagttgagt
661 agcttgatg cagagacgct gcagaaaaat catgaccagt tcgccacggg cagcggccct
721 cttcgtggca gtatcactca atgccaaggg ctgatgcagt tttgtggtgg ggaattgcaa
781 gctgaggcca gtgccattht aaacacgcct gtttgtggta ttcccttctc gcagtgaggga
841 actgttggtg gggcggccag cgcgtacgtc gccagtggtg ttgatctaac gcaggcagca
901 aatgagatca aagggctggg gcaacagatg cagcaattac tgtcattgat gtgatatgga
961 taaaaacaag ggggtagtgt ttcccccttt ttctatcaat attgcgaata tcttcgtccc
1021 tgatctttca ggggcgaatc gtttttttagc atgctcattg ttagaatttc tgacttatct
1081 ctcttctgta ttactactca tactctggaa aatcctgagc atttatatct atggattgat
1141 gcagcactcg ag

```

FIGURE 4

```

1      agggcattgg aattaaaaat atatttatct aaatgatgat gagtttaa at cattttgcg
61     tattaaaatg aataacgcat tattaacgta ttaccatctg ttcccgtta at tttttttaa
121    aaatttaagg taacaatgag tatatatctt atgggaaaag ccaaaaaact aacgaacact
181    ataataattc gattaacatc aatgaaaata cacggctcac ctattattaa aataatacga
241    ctagcattat aagaaaaaat attttttatg tttatagtat aggcgtgtat ttaattagtt
301    cttaatttaa ttaaggaggg aagcatgaac ttatcattaa gcgatcttca tcgtcaggta
361    tctcgattgg tgcagcaaga gagcgggtgat tgtaccggga aattaagagg taacgttgct
421    gccataaag aaactacctt tcaaggtttg accatagcca gtggtgccag agagtcagaa
481    aaagtatttg ctcaaaactgt actaagccac gtagcaaata ttgttctaac tcaagaagat
541    accgctaagc tattgcaaag cacggtaaag cataatttga ataattatga attaagaagt
601    gtcggcaatg gtaatagtgt acttgtcagt ttacgtagtg accaaatgac actacaagac
661    gccaaagtgc tgttgaggcg tgcattgcga caagagtcgg gagcgagggg gcatgtatca
721    tctcattcac attcagtcct tcacgcaccg ggaaccccgg tgcgtgaagg actgcgttca
781    catctagacc ccagaacacc accgttgcca ccgcgtgaac gaccacacac ttctggccat
841    cacggggctg gcgaagccag agccaccgca ccaagcactg tttctcetta tggcccagaa
901    gcgcgcgcag aactcagcag ccgcctcacc acattgcgca atacgctggc gccagcaacg
961    aatgatccgc gttacttaca agcctgcggc ggtgaaaagc taaaccgatt tagagatatt
1021   caatgctgtc ggcaaaccgc agtacgcgcc gatcttaatg ccaattacat ccaggtcggt
1081   aacactcgta ccatagcgtg ccagtatccg ctacaatctc aacttgaaag ccatttccgt
1141   atgctggcag aaaaccgaac gccagtgttg gctgttttag cgtccagttc tgagatagcc
1201   aatcaaagat tcggtatgcc agattatttc cgccagagtg gtacctatgg cagtatcact
1261   gtagagtcta aaatgactca gcaagtgggt ctcggtgacg ggattatggc agatatgtat
1321   actttaacga ttcgtgaagc gggtcaaaaa acaatttctg ttcctgtggg tcatgttggc
1381   aattggcccc atcagaccgc agtcagctct gaagttacca aggcactcgc ttcactggta
1441   gatcaaacag cagaaacaaa acgcaatatg tatgaaagca aaggaagttc agcggtagca
1501   gatgactcca aattacggcc ggtaatacat tgccgtgcgg gtgttggccg tactgcgcaa
1561   ctgattggcg caatgtgcat gaatgatagt cgtaatagtc agttaagcgt agaagatatg
1621   gtcagccaaa tgcgagtaca aagaaatggt attatggtac aaaaagatga gcaacttgat
1681   gttctgatta agttggctga aggacaaggg cgaccattat taaatagcta atgtaaatat
1741   ttattcctat gagtaaataa aattactaag agatatacac cactttgcca atcaaagaaa
1801   ctttaaacct caactaaagt aagcaattag ttgaggttta tctgctatag aataattatt
1861   aacaaaaata taaacaacaa aattaaaagt tatgtgtcta cttttacttt atgtaaccaa
1921   acccattaat ggataccgta cgtttttctt ttatagaatt aaaccagtaa atgagatgat
1981   gaaggacgat gatcatcgtc

```

FIGURE 5

6/7

```
1  atgattgggc caatatcaca aataaacagc ttcggtggct tatcagaaaa agagaccggt
61  tctttaatca gtaatgaaga gcttaaaaa atcataatac agttggaaac tgatatagcg
121 gatggatcct ggttccataa aaattattca cgcctggata tagaagtcac gcccgcat
181 gtaattcagg cgaacaataa atatccgga atgaatctta attttgttac atctccccag
241 gacctttcga tagaaataaa aaatgtcata gaaaatggag ttggatcttc ccgcttcata
301 attaacatgg gggagggtgg aatacatttc agtgtaattg attacaaaca tataaatggg
361 aaaacatctc tgatattatt tgaaccagta aactttaata gtatggggcc agcgatactg
421 gcaataagta caaaaacggc cattgaacgt tatcaattac ctgattgcc a tttttccatg
481 gtggaaatgg atattcagcg aagctcatct gaatgtggta tttttagttt ggcactggca
541 aaaaaacttt acaccgagag agatagcctg ttgaaaatac atgaagataa tataaaaggt
601 atattaagtg atagtgaata tccttttacc cacaataagt tggatccgta tctcccggt
661 actttttaca aacataactc aggtaaaaaa cgtcttaatg aatattttaa tactaaccgg
721 cagggagttg gtactgttgt taacaaaaaa aatgaaacca tctttaatag gtttgataac
781 aataaatcca ttatagatgg aaaggaatta tcagtttcgg tacataaaaa gagaatagct
841 gaatataaaa cacttctcaa agtataaa
```

FIGURE 6

7/7

CAGTGGTTTTTCTCTCTTTGAGAAGGGGTTGGTAAGATCTTTTCGGGGAAGATGTTTAACTTTTCAATTGCTCGT
AACCTTACTGAGACACTCCATGCAGCCCAGAAAACGACTTCGACGAGCTAAGGTCTGATATCCCAATGCTCTCA
GTAATCTCTTTGGAGCCAAGCCACAGACCGAACTGCCGCTGGGTTGGAAAGGGAAGCCTTTGTCAGGAGCTCCGGA
TCTTGAAGGGATGCGAGTGGCTGAAACCGATAAGTTTGCCGAGGGCGAAAGCCATATTAGTATAATAGAACTAAG
GATAATCAGCGGTTGGTGGCTAAGATTGAACGCTCCATTGCCGAGGGGCATTGTTCGCAGAACTGGAGGCTTATA
AACACATCTATAAAACCGCGGGCAAACATCCTAATCTTGCCAATGTCCATGGCATGGCTGTGGTGCCATACGGTAA
CCGTAAGGAGGAAGCATTGCTGATGGATGAGGTGGATGGTTGGCGTTGTTCTGACACACTAAGAAGCCTCGCCGAT
AGCTGGAAGCAAGGAAAGATCAATAGTGAAGCCTACTGGGGAACGATCAAGTTTATTGCCCATCGCTATTAGATG
TAACCAATCACCTTGCCAAGGCAGGGATAGTACATAACGATATCAAACCCGGTAATGTGGTATTTGACCGCGTAG
CGGAGAGCCCGTTGTCTATTGATCTAGGATTACACTCTCGTTCAGGGGAACAACCTAAGGGGTTTACAGAATCCTTC
AAAGCGCCGAGCTTGGAGTAGGAAACCTAGGCGCATCAGAAAAGAGCGATGTTTTTCTCGTAGTTTCAACCCTTC
TACATGGTATCGAAGTTTTGAGAAAGATCCGGAGATAAAGCCTAATCAAGGACTGAGATTCACTACCTCAGAACC
AGCGCACGTAATGGATGAGAATGGTTACCCAATCCATCGACCTGGTATAGCTGGAGTCGAGACAGCCTATACACGC
TTCATCACAGACATCCTTGGCGTTTCCGCTGACTCAAGACCTGATTCCAACGAAGCCAGACTCCACGAGTTCTTGA
GCGACGGAATATTGACGAGGAGTCGGCCAAGCAGATCCTAAAAGATACTCTAACCAGGAGAAATGAGCCATTATC
TACTGATGTAAGGCGGATAACACCCAAGAAGCTTCGGGAGCTCTCTGATTTGCTTAGGACGCATTGAGTAGTGCA
GCAACTAAGCAATTGGATATGGGGGTGGTTTTGTGCGGATCTTGATACCATGTTGGTGACACTCGACAAGGCCGAAC
GCGAGGGGGGAGTAGACAAGGATCAGTTGAAGAGTTTTAACAGTTTGATTCTGAAGACTTACAGCGTGATTGAAGA
CTATGTCAAAGGCAGAGAAGGGGATACCAAGAGTTCCAGTGCGGAAGTATCCCCCTATCATCGCAGTAACCTTTATG
CTATCGATCGCCGAACCTTCACTGCAGAGGATCCAAAAGCATCTGGACCAGACACACTCTTTTTCTGATATCGGTT
CACTAGTGCAGCACATAAGCACCTGGAACGCTTTTAGAGGTCTTAGTCACCTTGTCACCGCAAGGGCAGCCCGT
GTCTCTGAAACCTACAGCTTCTTGAATCGATTAGCTGAGGCTAAGGTCACCTTGTCGAGCAATTGGATACTCTC
CAGCAGCAGCAGGAGAGTGCGAAACGGCAACTATCTATTCTGATTAATCGTTTCAGGTTCTTGGGCCGATGTTGCTC
GTCAGTCCCTGCAGCGTTTGGACAGTACCCGGCCTGTAGTGAATTCGGCACTGAGCAGTATACCGCAATTCACCG
TCAGATGATGGCGGCCCATGCAGCCATTACGCTACAGGAGGTATCGGAGTTTACTGATGATATGCGAACTTTACA
GCGGACTCTATTCCACTACTGATTCGACTTGGACGAAGCAGTTAATAGATGAGCATTGGTTGAACAGAGAGAGA
AGTTGCGAGACGTGACGACCATCGCCGAGCGACTGAACCGGTTGGAGCGGGAATGGATGTGA

FIGURE 7

SEQUENCE LISTING

<110> van der Bruggen, Pierre

Cornelis, Guy R.

<120> DELIVERY OF PROTEINS INTO EUKARYOTIC CELLS

WITH RECOMBINANT *YERSINIA*

<130> 11154

<140> US 09/036,582

<141> 1998-03-06

<160> 39

<170> PatentIn Ver. 2.0

<210> 1

<211> 9

<212> PRT

<213> Human MAGE-1 peptide

<400> 1

Glu Ala Asp Pro Thr Gly His Ser Tyr

5

<210> 2

<211> 9

<212> PRT

<213> Human MAGE-1 peptide

<400> 2

Ser Ala Tyr Gly Glu Pro Arg Lys Leu
5

<210> 3

<211> 9

<212> PRT

<213> Human MAGE-3 peptide

<400> 3

Glu Val Asp Pro Ile Gly His Leu Tyr
5

<210> 4

<211> 9

<212> PRT

<213> Human MAGE-3 peptide

<400> 4

Phe Leu Trp Gly Pro Arg Ala Leu Val
5

<210> 5

<211> 10

<212> PRT

<213> Human MAGE-3 peptide

<400> 5

Met Glu Val Asp Pro Ile Gly His Leu Tyr
5 10

<210> 6

<211> 9

<212> PRT

<213> Human BAGE peptide

<400> 6

Ala Ala Arg Ala Val Phe Leu Ala Leu
5

<210> 7

<211> 8

<212> PRT

<213> Human GAGE-1,2 peptide

<400> 7

Tyr Arg Pro Arg Pro Arg Arg Tyr
5

<210> 8

<211> 10

<212> PRT

<213> Human RAGE peptide

<400> 8

Ser Pro Ser Ser Asn Arg Ile Arg Asn Thr
5 10

<210> 9

<211> 10

<212> PRT

<213> Human GnT-V peptide

<400> 9

Val Leu Pro Asp Val Phe Ile Arg Cys Val
5 10

<210> 10

<211> 9

<212> PRT

<213> Human MUM-1 peptide

<400> 10

Glu Glu Lys Leu Ile Val Val Leu Phe
5

<210> 11

<211> 9

<212> PRT

<213> Human MUM-1 peptide

<400> 11

Glu Glu Lys Leu Ser Val Val Leu Phe
5

<210> 12

<211> 10

<212> PRT

<213> Human CDK4 peptide

<400> 12

Ala Cys Asp Pro His Ser Gly His Phe Val
5 10

<210> 13

<211> 10

<212> PRT

<213> Human CDK4 peptide

<400> 13

Ala Arg Asp Pro His Ser Gly His Phe Val
5 10

<210> 14

<211> 9

<212> PRT

<213> Human β -catenin peptide

<400> 14

Ser Tyr Leu Asp Ser Gly Ile His Phe
5

<210> 15

<211> 9

<212> PRT

<213> Human β -catenin peptide

<400> 15

Ser Tyr Leu Asp Ser Gly Ile His Ser
5

<210> 16

<211> 9

<212> PRT

<213> Human Tyrosinase peptide

<400> 16

Met Leu Leu Ala Val Leu Tyr Cys Leu
5

<210> 17

<211> 9

<212> PRT

<213> Human Tyrosinase peptide

<400> 17

Tyr Met Asn Gly Thr Met Ser Gln Val
5

<210> 18

<211> 9

<212> PRT

<213> Human Tyrosinase peptide

<400> 18

Tyr Met Asp Gly Thr Met Ser Gln Val
5

<210> 19

<211> 9

<212> PRT

<213> Human Tyrosinase peptide

<400> 19

Ala Phe Leu Pro Trp His Arg Leu Phe
5

<210> 20

<211> 9

<212> PRT

<213> Human Tyrosinase peptide

<400> 20

Ser Glu Ile Trp Arg Asp Ile Asp Phe
5

<210> 21

<211> 9

<212> PRT

<213> Human Tyrosinase peptide

<400> 21

Tyr Glu Ile Trp Arg Asp Ile Asp Phe
5

<210> 22

<211> 15

<212> PRT

<213> Human Tyrosinase peptide

<400> 22

Gln	Asn	Ile	Leu	Leu	Ser	Asn	Ala	Pro	Leu	Gly	Pro	Gln	Phe	Pro
				5					10					15

<210> 23

<211> 15

<212> PRT

<213> Human Tyrosinase peptide

<400> 23

Asp	Tyr	Ser	Tyr	Leu	Gln	Asp	Ser	Asp	Pro	Asp	Ser	Phe	Gln	Asp
				5					10					15

<210> 24

<211> 10

<212> PRT

<213> Human Melan-A^{MART-1} peptide

<400> 24

Glu Ala Ala Gly Ile Gly Ile Leu Thr Val
5 10

<210> 25

<211> 9

<212> PRT

<213> Human Melan-A^{MART-1} peptide

<400> 25

Ile Leu Thr Val Ile Leu Gly Val Leu
5

<210> 26

<211> 9

<212> PRT

<213> Human gp100^{Pmel117} peptide

<400> 26

Lys Thr Trp Gly Gln Tyr Trp Gln Val
5

<210> 27

<211> 9

<212> PRT

<213> Human gp100^{Pme1117} peptide

<400> 27

Ile Thr Asp Gln Val Pro Phe Ser Val
5

<210> 28

<211> 9

<212> PRT

<213> Human gp100^{Pme1117} peptide

<400> 28

Tyr Leu Glu Pro Gly Pro Val Thr Ala
5

<210> 29

<211> 10

<212> PRT

<213> Human gp100^{Pme1117} peptide

<400> 29

Leu Leu Asp Gly Thr Ala Thr Leu Arg Leu
5 10

<210> 30

<211> 10

<212> PRT

<213> Human gp100^{Pme1117} peptide

<400> 30

Val Leu Tyr Arg Tyr Gly Ser Phe Ser Val
5 10

<210> 31

<211> 9

<212> PRT

<213> Human DAGE peptide

<400> 31

Leu Tyr Val Asp Ser Leu Phe Phe Leu
5

<210> 32

<211> 12

<212> PRT

<213> Human MAGE-6 peptide

<400> 32

Lys Ile Ser Gly Gly Pro Arg Ile Ser Tyr Pro Leu
 5 10

<210> 33

<211> 1330

<212> DNA

<213> *Yersinia enterocolitica*

<400> 33

```

AAAAATGGCC AAAA ACTTTC AATGGTAGAA GAGCTAAATT TGGATAAGTA ACGCATAAAA   60
ATTTTCGACG AAAA ACTATA TATATATATA TATTTAATAT GTATGGTTTC ATTTGCAATG  120
AAAAAACCGA TAATAAAGAT ATTTTCAGAA AGGCATTCAA TATGTTTATA AACCCAAGAA  180
ATGTATCTAA TACTTTTTTG CAAGAACCAT TACGTCATTC TTCTGATTTA ACTGAGATGC  240
CAGTTGAGGC AGAAAATGTT AAATCTAAGG CTGAATATTA TAATGCATGG TCGGAATGGG  300
AACGAAATGC CCCTCCGGGG AATGGTGAAC AGAGGGGAAT GGCGGTTTCA AGGTTACGCG  360
ATTGCCTGGA CCGACAAGCC CATGAGCTAG AACTAAATAA TCTGGGGCTG AGTTCTTTGC  420
CGGAATTACC TCCGCATTTA GAGAGTTTAG TGGCGTCATG TAATTCTCTT ACAGAAATTAC  480
CGGAATTGCC GCAGAGCCTG AAATCACTTC AAGTTGATAA TAACAATCTG AAGGCATTAT  540
CCGATTTACC TCCTTTACTG GAATATTTAG GTGCCGCTAA TAATCAGCTG GAAGAATTAC  600
CAGAGTTGCA AAACTCGTCC TTCTTGACAT CTATTGATGT TGATAACAAT TCACTGAAAA  660

```

CATTACCTGA TTTACCTCCT TCACTGGAAT TTCTTGCTGC TGGTAATAAT CAGCTGGAAG 720
 AATTGTCAGA GTTGCAAAAC TTGCCCTTCT TGA CTGCGAT TTATGCTGAT AACAATTCAC 780
 TGAAAACATT ACCCGATTTA CCCCCCTCCC TGAAAACACT TAATGTCAGA GAAAATTATT 840
 TAACTGATCT GCCAGAATTA CCGCAGAGTT TAACCTTCTT AGATGTTTCT GATAATATTT 900
 TTTCTGGATT ATCGGAATTG CCACCAAAC TGTATAATCT CAATGCATCC AGCAATGAAA 960
 TAAGATCTTT ATGCGATTTA CCCCCCTCAC TGGTAGAACT TGATGTCAGA GATAATCAGT 1020
 TGATCGAACT GCCAGCGTTA CCTCCACGCT TAGAACGTTT AATCGCTTCA TTTAATCATC 1080
 TTGCTGAAGT ACCTGAATTG CCGCAAAACC TGAAACTGCT CCACGTAGAG TACAACGCTC 1140
 TGAGAGAGTT TCCCAGATATA CCTGAGTCAG TGAAGATCT TCGGATGGAC TCTGAACGTG 1200
 TAATTGATCC ATATGAATTT GCTCATGAGA CTATAGACAA ACTTGAAGAT GATGTATTTG 1260
 AGTAGTGCGC AAGAGCGTTC ATAATTCTGC GTCACGTAA AATATCATT CAACGTAATC 1320
 ACTTTATCGA 1330

<210> 34

<211> 1152

<212> DNA

<213> *Yersinia enterocolitica*

<400> 34

GAATCCCCA ACTTTGACAC CGATAACCGG TTCAATAGTA TCTGGAATAG ACAGCGAAAG 60
 TTGTTGAAAT AATTGAGTGA TAGCTTGTTT AAATGAATAC ATTTGATCTC CTAATAGTTA 120
 GATAAAATAT CAACTTAACC AAAGCACTCT CGGCAGACCA TCAATTTTAG CCTATAATTT 180
 TTAGTTTTTA TTTTGTCTAA TATAACAACA AAAACAGCAG CGGTTTTTTA TATAACCACC 240
 GGCTATTTTC CCACTAAGAT AACCTTGTTT TAATAGCCAA GGAATAAAT AGTCATGAAA 300
 ATATCATCAT TTATTTCTAC ATCACTGCCC CTGCCGGCAT CAGTGTGAGG ATCTAGCAGC 360
 GTAGGAGAAA TGTCTGGGCG CTCAGTCTCA CAGCAAAAAA GTGATCAATA TGCAACAAT 420
 CTGGCCGGGC GCACTGAAAG CCCTCAGGGT TCCAGCTTAG CCAGCCGTAT CATTGAGAGG 480
 TTATCATCAA TGGCCCACTC TGTGATTGGA TTTATCCAAC GCATGTTCTC GGAGGGGAGC 540
 CATAAACCGG TGGTGACACC AGCACTCACG CCTGCACAAA TGCCAAGCCC TACGTCTTTC 600
 AGTGATAGTA TCAAGCAACT TGCTGCTGAG ACGCTGCCAA AATACATGCA GCAGTTGAGT 660

```

AGCTTGGATG CAGAGACGCT GCAGAAAAAT CATGACCAGT TCGCCACGGG CAGCGGCCCT 720
CTTCGTGGCA GTATCACTCA ATGCCAAGGG CTGATGCAGT TTTGTGGTGG GGAATTGCAA 780
GCTGAGGCCA GTGCCATTTT AACACGCCT GTTTGTGGTA TTCCCTTCTC GCAGTGGGGA 840
ACTGTTGGTG GGGCGGCCAG CGCGTACGTC GCCAGTGGCG TTGATCTAAC GCAGGCAGCA 900
AATGAGATCA AAGGGCTGGG GCAACAGATG CAGCAATTAC TGTCAATTGAT GTGATATGGA 960
TAAAAACAAG GGGGTAGTGT TTCCCCCTTT TTCTATCAAT ATTGCGAATA TCTTCGTCCC 1020
TGATCTTTCA GGGGCGAATC GTTTTTTAGC ATGCTCATTG TTAGAATTTC TGACTTATCT 1080
CTCTTCTGTA TTACTACTCA TACTCTGGAA AATCCTGAGC ATTTATATCT ATGGATTGAT 1140
GCAGCACTCG AG 1152

```

<210> 35

<211> 1990

<212> DNA

<213> *Yersinia enterocolitica*

<400> 35

```

AGGGCATTGG AATTAAAAAT ATATTTATCT AAATGATGAT GAGTTTAAAT TACATTTGCG 60
TATTAAAATG AATAACGCAT TATTAACGTA TTACCATCTG TTCCCGCTTA ATTTTTTAAA 120
AAATTTAAGG TAACAATGAG TATATATCTT ATGGGAAAAG CAAAAAACT AACGAACACT 180
ATAATAATTC GATTAACATC AATGAAAATA CACGGCTCAC CTATTATTAA AATAATACGA 240
CTAGCATTAT AAGAAAAAAT ATTTTTTATG TTTATAGTAT AGGCGTGTAT TTAATTAGTT 300
CTTAATTTAA TTAAGGAGGG AAGCATGAAC TTATCATTA GCGATCTTCA TCGTCAGGTA 360
TCTCGATTGG TGCAGCAAGA GAGCGGTGAT TGTACCGGGA AATTAAGAGG TAACGTTGCT 420
GCCAATAAAG AAACACCTT TCAAGGTTTG ACCATAGCCA GTGGTGCCAG AGAGTCAGAA 480
AAAGTATTTG CTCAAACCTGT ACTAAGCCAC GTAGCAAATA TTGTTCTAAC TCAAGAAGAT 540
ACCGCTAAGC TATTGCAAAG CACGGTAAAG CATAATTTGA ATAATTATGA ATTAAGAAGT 600
GTCGGCAATG GTAATAGTGT ACTTGTCAGT TTACGTAGTG ACCAAATGAC ACTACAAGAC 660

```

```

GCCAAAGTGC TGTGGAGGC TGCATTGCCA CAAGAGTCGG GAGCGAGGGG GCATGTATCA 720
TCTCATTCAC ATTCAGTCCT TCACGCACCG GGAACCCCGG TGCGTGAAGG ACTGCGTTCA 780
CATCTAGACC CCAGAACACC ACCGTTGCCA CCGCGTGAAC GACCACACAC TTCTGGCCAT 840
CACGGGGCTG GCGAAGCCAG AGCCACCGCA CCAAGCACTG TTTCTCCTTA TGGCCCAGAA 900
GCGCGCGCAG AACTCAGCAG CCGCCTCACC ACATTGCGCA ATACGCTGGC GCCAGCAACG 960
AATGATCCGC GTTACTTACA AGCCTGCGGC GGTGAAAAGC TAAACCGATT TAGAGATATT 1020
CAATGCTGTC GGCAAACCGC AGTACGCGCC GATCTTAATG CCAATTACAT CCAGGTCGGT 1080
AACACTCGTA CCATAGCGTG CCAGTATCCG CTACAATCTC AACTTGAAAG CCATTTCCGT 1140
ATGCTGGCAG AAAACCGAAC GCCAGTGTG GCTGTTTTAG CGTCCAGTTC TGAGATAGCC 1200
AATCAAAGAT TCGGTATGCC AGATTATTTT CGCCAGAGTG GTACCTATGG CAGTATCACT 1260
GTAGAGTCTA AAATGACTCA GCAAGTTGGT CTCGGTGACG GGATTATGGC AGATATGTAT 1320
ACTTTAACGA TTCGTGAAGC GGGTCAAAA ACAATTTCTG TTCTGTGGT TCATGTTGGC 1380
AATTGGCCCG ATCAGACCGC AGTCAGCTCT GAAGTTACCA AGGCACTCGC TTCACTGGTA 1440
GATCAAACAG CAGAAACAAA ACGCAATATG TATGAAAGCA AAGGAAGTTC AGCGGTAGCA 1500
GATGACTCCA AATTACGGCC GGTAATACAT TGCCGTGCGG GTGTTGGCCG TACTGCGCAA 1560
CTGATTGGCG CAATGTGCAT GAATGATAGT CGTAATAGTC AGTTAAGCGT AGAAGATATG 1620
GTCAGCCAAA TGCGAGTACA AAGAAATGGT ATTATGGTAC AAAAAGATGA GCAACTTGAT 1680
GTTCTGATTA AGTTGGCTGA AGGACAAGGG CGACCATTAT TAAATAGCTA ATGTAAATAT 1740
TTATTCCTAT GAGTAAATAA AATTACTAAG AGATATACAC CACTTTGCCA ATCAAAGAAA 1800
CTTTAAACCT CAACTAAAGT AAGCAATTAG TTGAGGTTTA TCTGCTATAG AATAATTATT 1860
AACAAAAATA TAAACAACAA AATTAAAAGT TATGTGTCTA CTTTACTTTT ATGTAACCAA 1920
ACCCATTAAT GGATACCGTA CGTTTTTCTT TTATAGAATT AAACCAGTAA ATGAGATGAT 1980
GAAGGACGAT GATCATCGTC 1990

```

<210> 36

<211> 867

<212> DNA

<213> *Yersinia enterocolitica*

<400> 36

```

ATGATTGGGC CAATATCACA AATAAACAGC TTCGGTGGCT TATCAGAAAA AGAGACCCGT 60
TCTTTAATCA GTAATGAAGA GCTTAAAAAT ATCATAATAC AGTTGGAAAC TGATATAGCG 120
GATGGATCCT GGTTCATATA AAATTATTCA CGCCTGGATA TAGAAGTCAT GCCCGCATTA 180
GTAATTCAGG CGAACAATAA ATATCCGGAA ATGAATCTTA ATTTTGTTAC ATCTCCCCAG 240
GACCTTTTCGA TAGAAATAAA AAATGTCATA GAAAATGGAG TTGGATCTTC CCGCTTCATA 300
ATTAACATGG GGGAGGGTGG AATACATTTT AGTGTAATTG ATTACAAACA TATAAATGGG 360
AAAACATCTC TGATATTATT TGAACCAGTA AACTTTAATA GTATGGGGCC AGCGATACTG 420
GCAATAAGTA CAAAAACGGC CATTGAACGT TATCAATTAC CTGATTGCCA TTTTTCATG 480
GTGGAAATGG ATATTCAGCG AAGCTCATCT GAATGTGGTA TTTTGTAGTTT GGCACCTGGCA 540
AAAAAACTTT ACACCGAGAG AGATAGCCTG TTGAAAATAC ATGAAGATAA TATAAAAGGT 600
ATATTAAGTG ATAGTGAAAA TCCTTTACCC CACAATAAGT TGGATCCGTA TCTCCCGGTA 660
ACTTTTTTACA AACATACTCA AGGTAAAAAA CGTCTTAATG AATATTTAAA TACTAACCCG 720
CAGGGAGTTG GTACTGTTGT TAACAAAAAA AATGAAACCA TCTTTAATAG GTTTGATAAC 780
AATAAATCCA TTATAGATGG AAAGGAATTA TCAGTTTCGG TACATAAAAA GAGAATAGCT 840
GAATATAAAA CACTTCTCAA AGTATAA 867

```

<210> 37

<211> 2190

<212> DNA

<213> *Yersinia enterocolitica*

<400> 37

```

ATGAAAATCA TGGGAACAT GCCACCGTCG ATCTCCCTCG CCAAAGCTCA TGAGCGCATC 60
AGCCAACATT GGCAAAATCC TGTCGGTGAG CTCAATATCG GAGGAAAACG GTATAGAATT 120
ATCGATAATC AAGTGCTGCG CTTGAACCCC CACAGTGGTT TTTCTCTCTT TCGAGAAGGG 180

```

GTTGGTAAGA	TCTTTTCGGG	GAAGATGTTT	AACTTTTCAA	TTGCTCGTAA	CCTTACTGAG	240
ACACTCCATG	CAGCCCAGAA	AACGACTTCG	CAGGAGCTAA	GGTCTGATAT	CCCCAATGCT	300
CTCAGTAATC	TCTTTGGAGC	CAAGCCACAG	ACCGAACTGC	CGCTGGGTTG	GAAAGGGAAG	360
CCTTTGTCAG	GAGCTCCGGA	TCTTGAAGGG	ATGCGAGTGG	CTGAAACCGA	TAAGTTTGCC	420
GAGGGCGAAA	GCCATATTAG	TATAATAGAA	ACTAAGGATA	ATCAGCGGTT	GGTGGCTAAG	480
ATTGAACGCT	CCATTGCCGA	GGGGCATTTG	TTCGCAGAAC	TGGAGGCTTA	TAAACACATC	540
TATAAAACCG	CGGGCAAACA	TCCTAATCTT	GCCAATGTCC	ATGGCATGGC	TGTGGTGCCA	600
TACGGTAACC	GTAAGGAGGA	AGCATTGCTG	ATGGATGAGG	TGGATGGTTG	GCGTTGTTCT	660
GACACACTAA	GAAGCCTCGC	CGATAGCTGG	AAGCAAGGAA	AGATCAATAG	TGAAGCCTAC	720
TGGGGAACGA	TCAAGTTTAT	TGCCCATCGG	CTATTAGATG	TAACCAATCA	CCTTGCCAAG	780
GCAGGGATAG	TACATAACGA	TATCAAACCC	GGTAATGTGG	TATTTGACCG	CGCTAGCGGA	840
GAGCCCGTTG	TCATTGATCT	AGGATTACAC	TCTCGTTCAG	GGGAACAACC	TAAGGGGTTT	900
ACAGAATCCT	TCAAAGCGCC	GGAGCTTGGA	GTAGGAAACC	TAGGCGCATC	AGAAAAGAGC	960
GATGTTTTTC	TCGTAGTTTC	AACCCTTCTA	CATGGTATCG	AAGGTTTTGA	GAAAGATCCG	1020
GAGATAAAGC	CTAATCAAGG	ACTGAGATTC	ATTACCTCAG	AACCAGCGCA	CGTAATGGAT	1080
GAGAATGGTT	ACCCAATCCA	TCGACCTGGT	ATAGCTGGAG	TCGAGACAGC	CTATACACGC	1140
TTCATCACAG	ACATCCTTGG	CGPTTCCGCT	GACTCAAGAC	CTGATTCCAA	CGAAGCCAGA	1200
CTCCACGAGT	TCTTGAGCGA	CGGAACTATT	GACGAGGAGT	CGGCCAAGCA	GATCCTAAAA	1260
GATACTCTAA	CCGAGAGAAAT	GAGCCCATTA	TCTACTGATG	TAAGGCGGAT	AACACCCAAAG	1320
AAGCTTCGGG	AGCTCTCTGA	TTTGCTTAGG	ACGCATTTGA	GTAGTGCAGC	AACTAAGCAA	1380
TTGGATATGG	GGGTGGTTTT	GTCGGATCTT	GATACCATGT	TGGTGACACT	CGACAAGGCC	1440
GAACGCGAGG	GGGGAGTAGA	CAAGGATCAG	TTGAAGAGTT	TTAACAGTTT	GATTCTGAAG	1500
ACTTACAGCG	TGATTGAAGA	CTATGTCAAA	GGCAGAGAAG	GGGATACCAA	GAGTTCCAGT	1560
GCGGAAGTAT	CCCCCTATCA	TCGCAGTAAC	TTTATGCTAT	CGATCGCCGA	ACCTTCACTG	1620
CAGAGGATCC	AAAAGCATCT	GGACCAGACA	CACTCTTTTT	CTGATATCGG	TTCACTAGTG	1680
CGCGCACATA	AGCACCTGGA	AACGCTTTTA	GAGGTCTTAG	TCACCTTGTC	ACCGCAAGGG	1740
CAGCCCGTGT	CCTCTGAAAC	CTACAGCTTC	CTGAATCGAT	TAGCTGAGGC	TAAGGTCACC	1800
TTGTGCGAGC	AATTGGATAC	TCTCCAGCAG	CAGCAGGAGA	GTGCGAAACG	GCAACTATCT	1860
ATTCTGATTA	ATCGTTCAGG	TTCTTGGGCC	GATGTTGCTC	GTCAGTCCCT	GCAGCGTTTT	1920
GACAGTACCC	GGCCTGTAGT	GAAATTCCGGC	ACTGAGCAGT	ATACCGCAAT	TCACCGTCAG	1980
ATGATGGCGG	CCCATGCAGC	CATTACGCTA	CAGGAGGTAT	CGGAGTTTAC	TGATGATATG	2040
CGAAACTTTA	CAGCGGACTC	TATTCCACTA	CTGATTTCGAC	TTGGACGAAG	CAGTTTAATA	2100
GATGAGCATT	TGGTTGAACA	GAGAGAGAAG	TTGCGAGACG	TGACGACCAT	CGCCGAGCGA	2160
CTGAACCGGT	TGGAGCGGGA	ATGGATGTGA				2190

<210> 38

<211> 31

<212> DNA

<213> *Yersinia enterocolitica*

<400> 38

AAACTGCAGA TGTCTCTTGA GCAGAGGAGT C

31

<210> 39

<211>

<212> DNA

<213> *Yersinia enterocolitica*

<400> 39

AAACTGCAGT CAGACTCCCT CTCCTCCTC

30